Details of Disease

General Information of Disease (ID: DISF7HVM)

Disease Name	Amyotrophic lateral sclerosis
Synonyms	motor neuron disease, bulbar; Lou Gehrig's disease; amyotrophic lateral sclerosis; Charcot disease; ALS; Lou Gehrig disease
Disease Class	8B60: Motor neuron disease
Definition	Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive muscular paralysis reflecting degeneration of motor neurons in the primary motor cortex, corticospinal tracts, brainstem and spinal cord.
Disease Hierarchy	DISF6XLX: Anterior horn disorder DISUHWUI: Motor neurone disease DISF7HVM: Amyotrophic lateral sclerosis
ICD Code	ICD-11 ICD-11: 8B60.0 ICD-9 ICD-9: 335.2 Expand ICD-11 '8B60.0 Expand ICD-9 335.2
Disease Identifiers	MONDO ID MONDO_0004976 MESH ID D000690 UMLS CUI C0002736 MedGen ID 274 HPO ID HP:0007354 Orphanet ID 803 SNOMED CT ID 86044005

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 5 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Ibudilast	DM4LSPN	Approved	Small molecular drug	[1]
MCI-186	DM8ZHP1	Approved	Small molecular drug	[2]
Pioglitazone	DMKJ485	Approved	Small molecular drug	[3]
Riluzole	DMECBWN	Approved	Small molecular drug	[4]
Tofersen	DM0AEDT	Approved	Antisense oligonucleotide	[5]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 41 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AL-02	DM450I4	Phase 3	NA	[6]
ALS 001	DMSXOJL	Phase 3	Cell therapy	[7]
AQST-117	DMORP5T	Phase 3	NA	[1]
CK-2017357	DMJ9ZIY	Phase 3	Small molecular drug	[8]
Donaperminogene seltoplasmid	DMH8IT5	Phase 3	Gene therapy	[9]
GSK4527223	DMXLD07	Phase 3	Antibody	[10]
ION363	DM2J3CX	Phase 3	Antisense oligonucleotide	[11]
Masitinib	DMRSNEU	Phase 3	Small molecular drug	[8]
NurOwn	DMZ9LRY	Phase 3	NA	[1]
VM-202	DMSW80U	Phase 3	NA	[8]
AMX0035	DMR32AS	Phase 2	NA	[1]
AT-1501	DMQIA5K	Phase 2	Antibody	[12]
BIIB105	DMLMUK6	Phase 2	Antisense oligonucleotide	[13]
BLZ-945	DMG1LVA	Phase 2	Small molecular drug	[14]
CK-2127107	DM9FHV8	Phase 2	NA	[1]
CORT113176	DMK6IIN	Phase 2	Small molecule	[15]
EPI 589	DMZT7EP	Phase 2	NA	[1]
FLX-787	DMQX5UA	Phase 2	NA	[1]
GM-602	DM8R4YU	Phase 2	NA	[1]
GM06	DM32TMS	Phase 2	NA	[8]
H.P. Acthar Gel	DMI6L3B	Phase 2	NA	[8]
IONIS-C9Rx	DM6PDX2	Phase 2	Antisense oligonucleotide	[16]
IONIS-SOD111RX	DMJY9T5	Phase 2	NA	[8]
KPAX002	DMDT5WM	Phase 2	NA	[1]
Mesenchymal stromal cells secreting neurotrophic factors	DMJ9E37	Phase 2	NA	[8]
NP001	DMVB5E1	Phase 2	Small molecular drug	[17]
NSI-566	DMHHXC9	Phase 2	NA	[1]
Procysteine	DMF9RB4	Phase 2	Small molecular drug	[18]
RNS-60	DMDNRU1	Phase 2	NA	[1]
RNS60	DMTHZ2V	Phase 2	NA	[19]
SAR443820	DMNCP7B	Phase 2	Small molecule	[20]
Cu(II)ATSM	DM5I2CC	Phase 1/2	NA	[1]
BHV-0223	DMBLM5H	Phase 1	NA	[1]
BRX-005	DMTDWIE	Phase 1	Small molecular drug	[21]
CC-100	DM2AYUX	Phase 1	Small molecular drug	[1]
CC100	DMB867J	Phase 1	NA	[22]
DNL747	DMNSC0O	Phase 1	Small molecular drug	[23]
GDC0134	DMSE19U	Phase 1	NA	[1]
ISIS-SOD1	DMV1BTP	Phase 1	Antisense drug	[24]
NPT520-34	DMVFDGE	Phase 1	Small molecule	[25]
RPI-MN	DM5OXPZ	Phase 1	NA	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 41 Drug(s)

This Disease is Treated as An Indication in 3 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Brain derived neurotrophic factor	DMREO9B	Discontinued in Phase 2	NA	[26]
FP0011	DMPU5WD	Discontinued in Phase 2	NA	[27]
T-588	DM3M5TU	Discontinued in Phase 2	Small molecular drug	[28]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 1 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
M102	DMUFIO9	Preclinical	NA	[29]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 411 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
UBQLN2	OT7VD5NH	Supportive	Autosomal dominant	[30]
VAPB	OT9ZTZH0	Supportive	Autosomal dominant	[31]
VCP	OTWIX1JU	Supportive	Autosomal dominant	[30]
A1BG	OTFVUGNQ	Limited	Biomarker	[248]
ACAT2	OTZ092ZJ	Limited	Biomarker	[249]
ACTN3	OT9DZ7JQ	Limited	Biomarker	[250]
ACY1	OT9WU7X3	Limited	Biomarker	[251]
ADAMTS3	OT2U6VF5	Limited	Biomarker	[35]
ADARB2	OTDJKS39	Limited	Altered Expression	[252]
AGFG1	OTI8ZKC4	Limited	Biomarker	[147]
AK4	OTA0T02Q	Limited	Altered Expression	[253]
AMPH	OTWPGWZX	Limited	Genetic Variation	[254]
APEX1	OT53OI14	Limited	Autosomal dominant	[39]
APH1A	OT97F1TU	Limited	Biomarker	[255]
AQP4	OTA9MYD5	Limited	Biomarker	[256]
ARPP21	OTWXZN5I	Limited	Autosomal dominant	[46]
ASAP1	OT4DLRYY	Limited	Biomarker	[257]
ASAP2	OTGEXULW	Limited	Biomarker	[257]
ATG4B	OTQ4RNRM	Limited	Altered Expression	[258]
ATL1	OTR2788Y	Limited	Genetic Variation	[259]
ATP5F1A	OT3FZDLX	Limited	Biomarker	[260]
ATP6	OTPHOGLX	Limited	Biomarker	[261]
AZIN2	OT8OB7CG	Limited	Biomarker	[262]
BBS2	OTPF9JIB	Limited	Biomarker	[263]
BCL11B	OT8KKCVJ	Limited	Biomarker	[264]
BICD2	OTVJ03NZ	Limited	Genetic Variation	[265]
BLZF1	OT5QD8FG	Limited	Biomarker	[266]
BNIP1	OT7USYCY	Limited	Biomarker	[267]
BNIP3L	OTJKOMXE	Limited	Biomarker	[268]
BTBD10	OTFPYPZE	Limited	Biomarker	[269]
CABIN1	OT4G5CIK	Limited	Genetic Variation	[270]
CALB2	OTSNMCG9	Limited	Biomarker	[271]
CAMK1G	OT1VEDLV	Limited	Biomarker	[270]
CAMK4	OT47RDGV	Limited	Biomarker	[272]
CAV1	OTEZUR1L	Limited	Autosomal dominant	[46]
CAV2	OT1FGRQX	Limited	Autosomal dominant	[46]
CCL4L2	OTDBSXOU	Limited	Altered Expression	[273]
CD2AP	OTC76KQM	Limited	Biomarker	[274]
CDKN2D	OT2TTZPZ	Limited	Biomarker	[275]
CEACAM4	OT0C7YUD	Limited	Biomarker	[51]
CEBPD	OTNBIPMY	Limited	Biomarker	[276]
CHST2	OTV11IZF	Limited	Genetic Variation	[277]
CLDN5	OTUX60YO	Limited	Altered Expression	[278]
CLEC4C	OT8ZOPCE	Limited	Autosomal dominant	[39]
CREB5	OTJDUJPI	Limited	Altered Expression	[279]
CRYM	OTRGSR6B	Limited	Biomarker	[280]
CYFIP2	OTCAY35T	Limited	Biomarker	[97]
CYLD	OT37FKH0	Limited	Autosomal dominant	[39]
DBR1	OTLTWLTE	Limited	Altered Expression	[281]
DCX	OTISR7K3	Limited	Altered Expression	[282]
DDX3X	OTDO4TRX	Limited	Altered Expression	[53]
DECR1	OTCDIR6X	Limited	Altered Expression	[44]
DNAJB9	OT38EQT6	Limited	Altered Expression	[168]
DNAJC7	OTQ5AL3F	Limited	Autosomal dominant	[46]
EFNA5	OTOH4DRR	Limited	Altered Expression	[283]
EFNB1	OT7JJW8P	Limited	Biomarker	[284]
ELAVL4	OT3YH6J6	Limited	Biomarker	[285]
ERGIC1	OT351FKB	Limited	Genetic Variation	[267]
ERLIN1	OTUOOODY	Limited	Autosomal recessive	[46]
FADS3	OT9RVXGE	Limited	Altered Expression	[286]
FAM20C	OTW5YZ7X	Limited	Genetic Variation	[287]
FCN3	OTPRENLS	Limited	Biomarker	[288]
FLCN	OTVM78XM	Limited	Biomarker	[289]
FLVCR1	OT9XCFOC	Limited	Biomarker	[95]
FTL	OTYQA8A6	Limited	Altered Expression	[61]
FZD2	OT952ML1	Limited	Biomarker	[290]
GADL1	OTJM4A0R	Limited	Biomarker	[262]
GDF11	OTOSNMND	Limited	Biomarker	[291]
GEMIN6	OTE262KF	Limited	Biomarker	[292]
GGNBP2	OT7K9YZV	Limited	Genetic Variation	[293]
GLT8D1	OTG14TPO	Limited	Biomarker	[294]
GLYAT	OT3WWYXD	Limited	Biomarker	[295]
GRIN3B	OT7T1OJP	Limited	Biomarker	[296]
HADHA	OTO557N2	Limited	Biomarker	[249]
HLA-DRB5	OTUX5TWM	Limited	Genetic Variation	[297]
HLA-F	OT76CM19	Limited	Biomarker	[298]
HNRNPA3	OT4O4NFS	Limited	Biomarker	[299]
HNRNPK	OTNPRM8U	Limited	Biomarker	[300]
HOMER1	OTWFD3SI	Limited	Genetic Variation	[301]
HTRA2	OTC7616F	Limited	Biomarker	[302]
IFRD1	OT4SQMLQ	Limited	Altered Expression	[279]
IFT74	OTZBFEDD	Limited	Genetic Variation	[303]
INA	OT1D33T4	Limited	Biomarker	[304]
INPP5B	OT0SC8W5	Limited	Genetic Variation	[305]
JDP2	OTW35WKX	Limited	Genetic Variation	[306]
JPH3	OTHTJO2I	Limited	Genetic Variation	[307]
JTB	OT314JB6	Limited	Biomarker	[308]
KCNIP1	OTGLGK1R	Limited	Genetic Variation	[309]
KCNJ8	OTZ8G8FE	Limited	Altered Expression	[33]
KIF5B	OTT34MT8	Limited	Biomarker	[310]
L3MBTL1	OT8M52QY	Limited	Biomarker	[78]
LAMC1	OTIG527N	Limited	Altered Expression	[311]
LGALS4	OTKQCG0H	Limited	Genetic Variation	[312]
LGALSL	OTC983KJ	Limited	Unknown	[46]
LILRA2	OT1O2K47	Limited	Biomarker	[276]
LXN	OTZQ2M6Y	Limited	Biomarker	[313]
LY6E	OTMG16BZ	Limited	Biomarker	[314]
LZTS3	OTFFMOJN	Limited	Genetic Variation	[187]
MAGEE1	OTOQQO2X	Limited	Biomarker	[70]
MAP1B	OTVXW089	Limited	Biomarker	[315]
MCIDAS	OTK1JVAH	Limited	Biomarker	[316]
MDH1	OTJEO4E8	Limited	Genetic Variation	[317]
MED19	OTT9RT5N	Limited	Genetic Variation	[318]
MEF2A	OTV2SF6E	Limited	Biomarker	[319]
MEF2C	OTZGF1Y5	Limited	Biomarker	[319]
MGRN1	OTFZC41K	Limited	Biomarker	[320]
MMP28	OTHQZXM1	Limited	Biomarker	[321]
MNX1	OTXP9FH1	Limited	Altered Expression	[322]
MRPS30	OTDXIAGG	Limited	Biomarker	[257]
MTPAP	OT6HQ02S	Limited	Biomarker	[257]
MYBPH	OTQJBPUR	Limited	Biomarker	[323]
MYH6	OT3YNCH1	Limited	Genetic Variation	[324]
MYO6	OTJQYRC7	Limited	Genetic Variation	[324]
MYOD1	OTV2S79X	Limited	Altered Expression	[325]
NAP1L1	OTI7WBZV	Limited	Altered Expression	[326]
NEFH	OTMSCW5I	Limited	Autosomal dominant	[46]
NEUROG1	OTMJZP9G	Limited	Biomarker	[327]
NFIL3	OTQH9HM3	Limited	Altered Expression	[328]
NGB	OTW0SIUY	Limited	Biomarker	[329]
NLN	OTFRITPU	Limited	Biomarker	[330]
NMD3	OTXC5APO	Limited	Genetic Variation	[73]
NOC2L	OTNT7R33	Limited	Biomarker	[331]
NONO	OTN36Q6U	Limited	Biomarker	[332]
NOP53	OTA2YKO6	Limited	Biomarker	[333]
NOX1	OTZPJQCC	Limited	Genetic Variation	[334]
NRF1	OTOXWNV8	Limited	Altered Expression	[93]
NRGN	OTVGE10W	Limited	Biomarker	[335]
NT5C3B	OT5WAX2N	Limited	Genetic Variation	[293]
NUDT1	OTZSES3W	Limited	Altered Expression	[336]
NUP107	OTG4RDYS	Limited	Biomarker	[337]
NUP205	OTJKHCY6	Limited	Biomarker	[337]
OLFM1	OTOYPEWW	Limited	Genetic Variation	[338]
OLIG2	OTMCN6D3	Limited	Biomarker	[339]
OSBP	OT7R0OQQ	Limited	Biomarker	[340]
OSBPL3	OT9G194Y	Limited	Biomarker	[340]
P2RX2	OT0LF34A	Limited	Biomarker	[85]
P2RX6	OT1FNTXA	Limited	Biomarker	[85]
PABPN1	OT3MC5SE	Limited	Altered Expression	[341]
PANX1	OTXPEDOK	Limited	Biomarker	[342]
PAPOLA	OTPHD65D	Limited	Biomarker	[257]
PCBP1	OTHN0TD7	Limited	Biomarker	[343]
PDAP1	OTJSWMOD	Limited	Biomarker	[257]
PDSS1	OTXGVHAB	Limited	Biomarker	[344]
PFN2	OT5SSSA7	Limited	Biomarker	[345]
PICK1	OT8QE6EU	Limited	Biomarker	[346]
PINK1	OT50NR57	Limited	Biomarker	[347]
PLCD1	OT6WFVXZ	Limited	Biomarker	[348]
POLDIP3	OTTB5SV7	Limited	Genetic Variation	[349]
PPARGC1A	OTHCDQ22	Limited	Biomarker	[350]
PPIL2	OTL9Y4IO	Limited	Biomarker	[145]
PPP1R15A	OTYG179K	Limited	Biomarker	[351]
PRMT8	OT3MRK62	Limited	Genetic Variation	[352]
PRPH	OT6VUH78	Limited	Autosomal dominant	[46]
PSAP	OTUOEKY7	Limited	Biomarker	[353]
PSMA7	OTPHI6ST	Limited	Biomarker	[354]
PTPRN	OTAP7NOL	Limited	Biomarker	[355]
PURA	OT975ELW	Limited	Biomarker	[289]
RAB1A	OTKPHRD0	Limited	Biomarker	[356]
RAB29	OTDZT6LP	Limited	Biomarker	[357]
RAMP3	OTX6XLLM	Limited	Biomarker	[358]
RANGAP1	OTZGD3LJ	Limited	Biomarker	[359]
RAPGEF2	OTZWX2AA	Limited	Autosomal dominant	[39]
REST	OTLL92LQ	Limited	Biomarker	[329]
RNF112	OT0Q9OUQ	Limited	Biomarker	[360]
RPS17	OTWHZ2JQ	Limited	Biomarker	[261]
RPS25	OTKLWED2	Limited	Biomarker	[361]
RPS27A	OTIIGGZ2	Limited	Biomarker	[112]
SAGE1	OT4H6FFA	Limited	Altered Expression	[362]
SCG2	OTXWUQQL	Limited	Biomarker	[363]
SCNN1A	OTE2KVZV	Limited	Genetic Variation	[364]
SEL1L	OTC0FB7T	Limited	Altered Expression	[168]
SH2D1A	OTLU49I5	Limited	Biomarker	[38]
SMCR8	OT52BQH4	Limited	Biomarker	[365]
SOD3	OTIOZQAB	Limited	Biomarker	[226]
SPAG8	OTZC5XP9	Limited	Genetic Variation	[366]
SRCIN1	OTQZNQQ5	Limited	Biomarker	[367]
SUMO2	OT1Y5IKN	Limited	Genetic Variation	[368]
SUMO3	OTTUJQJ1	Limited	Biomarker	[368]
SYNJ1	OTTE02XC	Limited	Genetic Variation	[305]
SYNJ2	OTLRHXP1	Limited	Genetic Variation	[305]
SYT9	OT7S8WU0	Limited	Genetic Variation	[369]
TAAR6	OTUBUJ2N	Limited	Biomarker	[336]
TAF15	OTNE038N	Limited	Autosomal dominant	[46]
TBCB	OTHZGAC4	Limited	Biomarker	[370]
TIA1	OTGPN3P8	Limited	Genetic Variation	[371]
TRIM69	OTTEGTRD	Limited	Biomarker	[107]
TSBP1	OT5GE8IO	Limited	Biomarker	[372]
TTBK2	OT90YSM5	Limited	Biomarker	[111]
ACTA1	OTOVGLPG	Disputed	Altered Expression	[373]
AFF2	OTMF1PZW	Disputed	Biomarker	[374]
CALCOCO2	OTRGX0OV	Disputed	Biomarker	[123]
CHRNG	OTXC2UR7	Disputed	Altered Expression	[117]
CUEDC2	OTWMOLAJ	Disputed	Biomarker	[375]
EIF3K	OTGTKVGO	Disputed	Biomarker	[376]
GLCE	OTPRSHX5	Disputed	Biomarker	[377]
GPX7	OTINT9Z4	Disputed	Biomarker	[378]
IFNGR1	OTCTQBWW	Disputed	Biomarker	[171]
MCU	OTQZAYWQ	Disputed	Altered Expression	[379]
OGA	OT7ZBWT1	Disputed	Biomarker	[378]
SPDYA	OTYKC1AJ	Disputed	Biomarker	[380]
SUPT4H1	OTB3UCTB	Disputed	Biomarker	[381]
ANG	OT3ECS6P	Supportive	Autosomal dominant	[118]
ANXA11	OT8SRY1C	Supportive	Autosomal dominant	[233]
CCNF	OTJFVU43	Supportive	Autosomal dominant	[382]
CFAP410	OTJ94J99	Supportive	Autosomal dominant	[184]
CHCHD10	OTCDHAM6	Supportive	Autosomal dominant	[383]
CHMP2B	OTZA7RJB	Supportive	Autosomal dominant	[384]
ERBB4	OT9L6C41	Supportive	Autosomal dominant	[119]
FIG4	OT501PY9	Supportive	Autosomal dominant	[30]
GLE1	OT0K44H1	Supportive	Autosomal dominant	[385]
HNRNPA1	OTIRPN6B	Supportive	Autosomal dominant	[120]
MATR3	OTESJ5S7	Supportive	Autosomal dominant	[386]
OPTN	OT2UXWH9	Supportive	Autosomal dominant	[30]
PFN1	OTHTGA1H	Supportive	Autosomal dominant	[387]
PON1	OTD0Z2XO	Supportive	Autosomal dominant	[244]
PON2	OT55NCTD	Supportive	Autosomal dominant	[244]
PON3	OT80W9TA	Supportive	Autosomal dominant	[244]
SOD1	OT39TA1L	Supportive	Autosomal dominant	[31]
SQSTM1	OTGY5D5J	Supportive	Autosomal dominant	[121]
TARDBP	OTVOSFWW	Supportive	Autosomal dominant	[30]
ALPP	OTZU4G9W	moderate	Biomarker	[123]
ALS2CL	OT8RY7TZ	moderate	Biomarker	[388]
ALYREF	OTOF2ADD	moderate	Biomarker	[40]
ANKRD1	OTHJ7JV9	moderate	Altered Expression	[389]
ANKRD2	OT4UYZ71	moderate	Altered Expression	[389]
ARHGEF28	OT3F32IU	Moderate	Autosomal dominant	[135]
ARHGEF7	OT9BPJCL	moderate	Biomarker	[390]
ATAD1	OTJ02XFL	moderate	Genetic Variation	[391]
ATP13A2	OTKWBUGK	moderate	Genetic Variation	[392]
ATRNL1	OTY5JUX2	moderate	Biomarker	[123]
ATXN1	OTQF0HNR	moderate	Biomarker	[393]
CALB1	OTM7IXDG	moderate	Genetic Variation	[394]
CARD16	OT4NUHWB	moderate	Biomarker	[395]
CAST	OTBXZZGF	moderate	Biomarker	[50]
CASZ1	OTWJ2OR8	moderate	Biomarker	[236]
CCDC88A	OT3SSYYC	moderate	Altered Expression	[396]
CCL27	OTUZYC61	moderate	Biomarker	[123]
CELSR3	OT8P6QNJ	moderate	Biomarker	[397]
CFDP1	OTXY7J96	moderate	Genetic Variation	[398]
CHI3L2	OT26R3HQ	moderate	Genetic Variation	[399]
COL4A2	OTJK1LKN	moderate	Altered Expression	[400]
COP1	OT6J2K12	moderate	Biomarker	[395]
CST7	OTQWZUVQ	moderate	Biomarker	[401]
CTBS	OT135K92	moderate	Biomarker	[143]
DAO	OTZFVRIN	Moderate	Autosomal dominant	[135]
DAPK2	OTWODUQG	moderate	Genetic Variation	[155]
DBNL	OTT2OQOV	moderate	Biomarker	[401]
DCTN1	OT5B51FJ	Moderate	Autosomal dominant	[46]
DCUN1D1	OT8UJLZU	moderate	Biomarker	[402]
DDX20	OT6G8YF3	moderate	Biomarker	[403]
DENR	OTXP9HOY	moderate	Genetic Variation	[155]
DERL1	OTJUS74N	moderate	Biomarker	[404]
EIF4G2	OTEO98CR	moderate	Genetic Variation	[398]
EWSR1	OT7SRHV3	Moderate	Autosomal dominant	[135]
FBXO32	OTUE978R	moderate	Biomarker	[405]
FGGY	OTLNEC2X	moderate	Biomarker	[406]
GAL3ST1	OTSFFZRD	moderate	Biomarker	[236]
GARS1	OT5B6R9Y	moderate	Biomarker	[407]
GEMIN2	OT4L6TLL	moderate	Biomarker	[408]
GEMIN4	OTX7402E	moderate	Genetic Variation	[398]
GFRA1	OT3WBVYB	moderate	Altered Expression	[409]
HNRNPA2B1	OTBZKX4P	Moderate	Autosomal dominant	[135]
KCNIP3	OTCQPEM4	moderate	Biomarker	[410]
LIG4	OT40DNXU	moderate	Biomarker	[411]
LRP4	OTO4M459	moderate	Biomarker	[412]
LSM2	OTHL77NY	moderate	Biomarker	[413]
MAP2	OT6UYT3X	moderate	Biomarker	[170]
MB	OTYWYL2D	moderate	Biomarker	[414]
MFN1	OTCBXQZF	moderate	Altered Expression	[93]
MOK	OTQK7M9V	moderate	Biomarker	[415]
MT1B	OTUA4FFH	moderate	Altered Expression	[416]
MTHFSD	OTB5ZUYF	moderate	Genetic Variation	[187]
NOP56	OTT67SRZ	moderate	Genetic Variation	[417]
PADI1	OT13WAQX	moderate	Genetic Variation	[418]
PDC	OT1UUVYY	moderate	Genetic Variation	[419]
PDIA2	OTC2WMXS	moderate	Genetic Variation	[418]
PDLIM3	OTVXQC81	moderate	Biomarker	[123]
PSMD2	OT6HZHN7	moderate	Genetic Variation	[398]
PVALB	OTZW1WVQ	moderate	Biomarker	[420]
RAB11A	OTC4FW0J	moderate	Biomarker	[421]
RAB5A	OTFR2KM4	moderate	Altered Expression	[422]
RANBP2	OTFG5CVF	moderate	Biomarker	[423]
RASGRF1	OTNWJ7EN	moderate	Biomarker	[424]
RHOT1	OTBIRR8Q	moderate	Altered Expression	[425]
RIPK3	OTL1D484	moderate	Biomarker	[426]
RRAD	OTW2O4GD	moderate	Biomarker	[427]
SCFD1	OTN4T7JI	moderate	Genetic Variation	[428]
SIL1	OTDI85I5	moderate	Biomarker	[429]
SNPH	OTL6XBFA	moderate	Altered Expression	[430]
SOS1	OTTCWXC3	moderate	Biomarker	[424]
SPAG11A	OTNQ9UB0	moderate	Altered Expression	[146]
SPAST	OTIF3AJI	moderate	Genetic Variation	[431]
SS18L1	OT9ZEGV7	Moderate	Autosomal dominant	[135]
STMN2	OT0FUHLH	moderate	Biomarker	[432]
TEAD1	OTK6971C	moderate	Altered Expression	[40]
TFEB	OTJUJJQY	moderate	Biomarker	[433]
TFPI2	OTZCRWOR	moderate	Altered Expression	[40]
A1CF	OTJBKFA1	Strong	Biomarker	[103]
AATF	OT1QOKLD	Strong	Biomarker	[434]
ACD	OTC54EPO	Strong	Biomarker	[435]
ADAR	OTQNOHR8	Strong	Biomarker	[252]
ADARB1	OTGKSZEV	Strong	Biomarker	[436]
ALS2	OT8BAM04	Strong	Biomarker	[437]
APTX	OTPAS5G8	Strong	Genetic Variation	[438]
ARAP2	OTBXYFRH	Strong	Genetic Variation	[212]
ARHGEF2	OTBQTFRT	Strong	Genetic Variation	[212]
ASPM	OTKXQMNA	Strong	Biomarker	[103]
ATF6	OTAFHAVI	Strong	Altered Expression	[439]
ATG14	OTPZDKI0	Strong	Biomarker	[435]
ATG5	OT4T5SMS	Strong	Biomarker	[373]
BSCL2	OT73V6Y4	Strong	Biomarker	[440]
C19orf12	OTVSJ1AR	Strong	Biomarker	[237]
CAMTA1	OTAN1S5B	Strong	Genetic Variation	[441]
CASP12	OTY2W6FG	Strong	Biomarker	[164]
CCS	OTXHT3QO	Strong	Biomarker	[358]
CENPV	OTPQ0KT9	Strong	Genetic Variation	[188]
CHAF1A	OTXSSY4H	Strong	Genetic Variation	[442]
CHGA	OTXYX5JH	Strong	Biomarker	[443]
CHI3L1	OT2Z7VJH	Strong	Biomarker	[64]
CLEC10A	OTD8HQT6	Strong	Altered Expression	[444]
CPNE4	OTTAGM5L	Strong	Genetic Variation	[212]
CTR9	OTP151PZ	Strong	Genetic Variation	[442]
CUX1	OTU1LCNJ	Strong	Biomarker	[178]
DCDC2	OTSUFH1H	Strong	Biomarker	[445]
DCTN4	OTM7C943	Strong	Genetic Variation	[180]
DES	OTI09KBW	Strong	Altered Expression	[446]
DNAJB2	OTZHPV5M	Strong	Genetic Variation	[447]
DNM1L	OTXK1Q1G	Strong	Altered Expression	[448]
ELP1	OTYEWBF7	Strong	Genetic Variation	[449]
ELP3	OTT5UKSZ	Strong	Biomarker	[450]
EPG5	OT3P5HQD	Strong	Biomarker	[451]
FIS1	OT2HL10J	Strong	Biomarker	[452]
FNDC3A	OTUX3S2I	Strong	Genetic Variation	[453]
GPX3	OT6PK94R	Strong	Genetic Variation	[454]
GRIP1	OT958HK1	Strong	Genetic Variation	[270]
GTF2H1	OTCRXC6B	Strong	Genetic Variation	[180]
GTPBP1	OTA9KV6C	Strong	Genetic Variation	[455]
HCLS1	OTX7WGYN	Strong	Biomarker	[178]
HNRNPC	OT47AK4C	Strong	Biomarker	[456]
HNRNPDL	OTB3BFCV	Strong	Biomarker	[456]
HNRNPH1	OTFRWOLM	Strong	Biomarker	[457]
HNRNPH2	OTMGP4J7	Strong	Biomarker	[457]
ICE1	OTOXTBUH	Strong	Genetic Variation	[455]
KHSRP	OTDHZARB	Strong	Biomarker	[178]
KIAA0040	OT27EBY3	Strong	Genetic Variation	[207]
KIAA0513	OT7AVTFB	Strong	Genetic Variation	[212]
KIF1B	OTI1XQTO	Strong	Genetic Variation	[458]
LAMA3	OTFME7HT	Strong	Genetic Variation	[212]
LMLN	OTQF0JPY	Strong	Biomarker	[185]
LMNB1	OT100T3P	Strong	Biomarker	[459]
MAK16	OTD546E5	Strong	Genetic Variation	[197]
MOB3B	OTZJQG1D	Strong	Genetic Variation	[460]
MSC	OTBRPZL5	Strong	Biomarker	[235]
MST1	OTOC4UNG	Strong	Biomarker	[185]
ND5	OT45LW1K	Strong	Genetic Variation	[193]
NEFM	OT8VCBNF	Strong	Altered Expression	[461]
NRXN1	OTJN1JQA	Strong	Genetic Variation	[207]
NUP62	OTMN63DH	Strong	Genetic Variation	[180]
NUP98	OTNT12G2	Strong	Biomarker	[436]
OXR1	OTPIDMT3	Strong	Biomarker	[462]
P4HB	OTTYNYPF	Strong	Genetic Variation	[418]
PDIA3	OTHPQ0Q3	Strong	Genetic Variation	[418]
PIK3R4	OTRL8QP8	Strong	Genetic Variation	[442]
PNO1	OT010GIS	Strong	Genetic Variation	[197]
PTPA	OTRGFOI7	Strong	Biomarker	[463]
RAB3GAP2	OTQTE0GI	Strong	Genetic Variation	[442]
RAG2	OTG9UYTW	Strong	Biomarker	[464]
RAN	OT2TER5M	Strong	Biomarker	[361]
RBM45	OTWTHD77	Strong	Biomarker	[289]
RBM8A	OT5SR6G0	Strong	Genetic Variation	[465]
RBMS3	OTFSC9MR	Strong	Genetic Variation	[197]
RNF19A	OTKWCV80	Strong	Biomarker	[466]
ROPN1L	OTRWZJ68	Strong	Biomarker	[103]
RREB1	OT62460U	Strong	Biomarker	[467]
SFPQ	OTLCIAPJ	Strong	Biomarker	[468]
SIGLEC7	OTNDLURR	Strong	Biomarker	[178]
SNRPN	OTQB1ID1	Strong	Biomarker	[213]
SRRM2	OTSIMMC9	Strong	Genetic Variation	[197]
ST3GAL3	OTOORKUE	Strong	Genetic Variation	[212]
STUB1	OTSUYI9A	Strong	Genetic Variation	[435]
SUGP1	OT7W0EB8	Strong	Biomarker	[469]
SUMO1	OTJFD4P5	Strong	Biomarker	[470]
SUN2	OT2IQJUC	Strong	Genetic Variation	[455]
SUN3	OTL5Z9NC	Strong	Genetic Variation	[471]
SUSD2	OTSJTAZP	Strong	Genetic Variation	[270]
TANK	OTZSGFIK	Strong	Genetic Variation	[472]
TFAM	OTXXV5V7	Strong	Biomarker	[473]
TFIP11	OT7NVSWU	Strong	Biomarker	[193]
THY1	OTVONVTB	Strong	Genetic Variation	[321]
TMED9	OTYGAQS0	Strong	Biomarker	[165]
TMEM106B	OTUWA6NW	Strong	Genetic Variation	[474]
TMPRSS13	OTMAOAP3	Strong	Biomarker	[185]
TNIP1	OTRAOTEW	Strong	Genetic Variation	[160]
TNPO1	OT7W2CM8	Strong	Genetic Variation	[475]
TPPP	OTCFMSUF	Strong	Biomarker	[165]
TSHZ1	OTYQ9ECW	Strong	Genetic Variation	[476]
CAPG	OTJ86KI6	Definitive	Biomarker	[170]
COL19A1	OT7W3Q87	Definitive	Biomarker	[477]
ERCC6L2	OTWFECWG	Definitive	Genetic Variation	[478]
FUS	OTPPNGQO	Definitive	Autosomal dominant	[220]
MLC1	OTCNZLSP	Definitive	Biomarker	[479]
MYH15	OTWZA8IF	Definitive	Genetic Variation	[480]
NGLY1	OTZBQD5Q	Definitive	Altered Expression	[481]
PLEC	OTU4XDEG	Definitive	Biomarker	[482]
PLP1	OT8CM9CX	Definitive	Biomarker	[483]
RMDN3	OTKO7AUM	Definitive	Biomarker	[484]
RUBCNL	OTMQIDOI	Definitive	Biomarker	[485]
SARM1	OTEP4I5O	Definitive	Biomarker	[486]
SPG11	OTZ7LJX4	Definitive	Biomarker	[487]
STXBP1	OTRYA8C3	Definitive	Biomarker	[149]
THEM4	OTSIZU8Y	Definitive	Altered Expression	[488]
------------------------------------------------------------------------------------


⏷ Show the Full List of 411 DOT(s)

This Disease Is Related to 220 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
AAK1	TT0Z32T	Limited	Altered Expression	[32]
ABCC9	TTEF5MJ	Limited	Genetic Variation	[33]
ADA	TTLP57V	Limited	Altered Expression	[34]
ADAMTS4	TTYG6BU	Limited	Biomarker	[35]
ADCYAP1R1	TT5OREU	Limited	Biomarker	[36]
AOC1	TTM3B5R	Limited	Biomarker	[37]
APCS	TTB7VAT	Limited	Biomarker	[38]
APEX1	TTHGL48	Limited	Autosomal dominant	[39]
APEX1	TTHGL48	Limited	Altered Expression	[40]
ATAT1	TTWUHQ1	Limited	Biomarker	[41]
CACNA1H	TTZPWGN	Limited	Biomarker	[42]
CACNA1S	TT94HRF	Limited	Genetic Variation	[43]
CARM1	TTIZQFJ	Limited	Altered Expression	[44]
CASP3	TTPF2QI	Limited	Altered Expression	[45]
CAV1	TTXUBN2	Limited	Autosomal dominant	[46]
CBR1	TTVG0SN	Limited	Altered Expression	[47]
CD40LG	TTIJP3Q	Limited	Therapeutic	[48]
CDC7	TTSMTDI	Limited	Biomarker	[49]
CDK5	TTL4Q97	Limited	Genetic Variation	[50]
CEACAM6	TTIGH2W	Limited	Biomarker	[51]
CLEC4C	TT7YT06	Limited	Autosomal dominant	[39]
CLEC4C	TT7YT06	Limited	Genetic Variation	[52]
CSNK1E	TTA8PLI	Limited	Altered Expression	[53]
CYBB	TT5T8MR	Limited	Altered Expression	[44]
DGAT1	TT0GV3R	Limited	Altered Expression	[54]
DNAJB1	TTPXAWS	Limited	Biomarker	[55]
ELAVL1	TTPC9D0	Limited	Biomarker	[56]
ERBB4	TTWALCO	Limited	Altered Expression	[57]
EREG	TTYSB89	Limited	Biomarker	[58]
FGFBP1	TTV1YFT	Limited	Altered Expression	[59]
FPR2	TTOJ1NF	Limited	Biomarker	[60]
FTH1	TT975ZT	Limited	Altered Expression	[61]
GBA	TT1B5PU	Limited	Biomarker	[62]
GCLM	TTNFESW	Limited	Biomarker	[63]
GFAP	TTI6FFX	Limited	Biomarker	[64]
GRIN2A	TTKJEMQ	Limited	Genetic Variation	[65]
GRM1	TTVBPDM	Limited	Altered Expression	[66]
GRM3	TT8A9EF	Limited	Biomarker	[67]
GSR	TTEP6RV	Limited	Biomarker	[68]
GSTP1	TT40K12	Limited	Biomarker	[69]
HCAR1	TTVK4ZO	Limited	Biomarker	[70]
HDAC11	TT8K17W	Limited	Altered Expression	[71]
HEXA	TTJI5JW	Limited	Genetic Variation	[72]
HNMT	TT2B6EV	Limited	Genetic Variation	[73]
HSPA8	TTMQL3K	Limited	Altered Expression	[74]
ID2	TTW8A5N	Limited	Biomarker	[75]
JAG2	TTOJY1B	Limited	Posttranslational Modification	[76]
KCNJ11	TT329V4	Limited	Genetic Variation	[33]
KCNT1	TTGJFK1	Limited	Genetic Variation	[77]
KMT5A	TTGC95K	Limited	Altered Expression	[78]
LTBR	TTFO0PM	Limited	Altered Expression	[79]
MAP4K3	TTI0AHJ	Limited	Genetic Variation	[80]
MC4R	TTD0CIQ	Limited	Genetic Variation	[81]
MCOLN1	TT9XBVO	Limited	Biomarker	[82]
MGAM	TTXWASR	Limited	Altered Expression	[83]
NEDD8	TTNDC4K	Limited	Biomarker	[84]
P2RX1	TTJW7B3	Limited	Biomarker	[85]
P2RX3	TT2THBD	Limited	Biomarker	[85]
P2RX7	TT473XN	Limited	Biomarker	[86]
P2RY12	TTZ1DT0	Limited	Genetic Variation	[87]
PABPC1	TTHC8EF	Limited	Biomarker	[88]
PAH	TTGSVH2	Limited	Biomarker	[89]
PCSK2	TT46F0P	Limited	Genetic Variation	[90]
PKN1	TTSL41O	Limited	Biomarker	[91]
PLA2G4A	TTT1JVS	Limited	Biomarker	[92]
PPARGC1B	TTKSQ3W	Limited	Altered Expression	[93]
PPID	TTNAFOU	Limited	Altered Expression	[94]
PPIF	TTRFQTB	Limited	Altered Expression	[94]
PTAFR	TTQL5VC	Limited	Biomarker	[95]
PTGER3	TTPNGDE	Limited	Genetic Variation	[96]
RBBP9	TTUA38Z	Limited	Biomarker	[97]
SIRT5	TTH0IOD	Limited	Altered Expression	[98]
SLC11A2	TT2IS7P	Limited	Genetic Variation	[99]
SLC12A4	TTJ8C67	Limited	Genetic Variation	[100]
SLC12A5	TTH6UZY	Limited	Altered Expression	[100]
SLC33A1	TTL69WB	Limited	Biomarker	[101]
SLC40A1	TT6Y1PG	Limited	Altered Expression	[102]
SLC6A1	TTPRKM0	Limited	Biomarker	[103]
SLC7A11	TTBZMIO	Limited	Altered Expression	[104]
SORT1	TTRX9AV	Limited	Genetic Variation	[105]
SOX5	TTXHSZK	Limited	Genetic Variation	[106]
TICAM1	TT2GQT6	Limited	Biomarker	[107]
TNFRSF21	TT8UA0T	Limited	Biomarker	[108]
TNKS	TTVUSO7	Limited	Biomarker	[109]
TPH2	TT3KLDP	Limited	Genetic Variation	[110]
TRIM27	TTTO3QN	Limited	Biomarker	[60]
TTBK1	TTYFAM9	Limited	Biomarker	[111]
UBC	TTBP3XA	Limited	Biomarker	[112]
UGCG	TTPHEX3	Limited	Genetic Variation	[113]
CSNK1D	TTH30UI	Disputed	Posttranslational Modification	[114]
CTSC	TT4H0V2	Disputed	Biomarker	[115]
DPYSL2	TTZCW3T	Disputed	Posttranslational Modification	[116]
MUSK	TT6SA0X	Disputed	Biomarker	[117]
ANG	TTURHFP	Supportive	Autosomal dominant	[118]
ERBB4	TTWALCO	Supportive	Autosomal dominant	[119]
HNRNPA1	TTPJ9XK	Supportive	Autosomal dominant	[120]
SQSTM1	TTOT2RY	Supportive	Autosomal dominant	[121]
TARDBP	TT9RZ03	Supportive	Autosomal dominant	[30]
VCP	TTYWTI0	Supportive	Autosomal dominant	[30]
AKT3	TTO6SGY	moderate	Altered Expression	[122]
ASRGL1	TT4WT91	moderate	Biomarker	[123]
ATG7	TTLVB9Z	moderate	Biomarker	[124]
CNTFR	TTT2F9E	moderate	Biomarker	[125]
CTF1	TTXGTZU	moderate	Biomarker	[126]
DAO	TT7Y3EJ	moderate	Biomarker	[127]
EIF2AK2	TTXEZJ4	moderate	Altered Expression	[128]
EPHA1	TTLFZVU	moderate	Altered Expression	[129]
EPHA3	TTHS2LR	moderate	Genetic Variation	[130]
GDA	TTK4JTZ	moderate	Biomarker	[131]
GRIA3	TT82EZV	moderate	Genetic Variation	[132]
GRIA4	TTPJR0G	moderate	Genetic Variation	[132]
GRIK1	TT0MYE2	moderate	Genetic Variation	[133]
HMOX2	TTWZRL4	moderate	Biomarker	[134]
HNRNPA2B1	TT8UPW6	Moderate	Autosomal dominant	[135]
HNRNPA2B1	TT8UPW6	moderate	Genetic Variation	[136]
ITPR2	TTK9OV3	moderate	Biomarker	[137]
KITLG	TTDJ51N	moderate	Altered Expression	[138]
MAOB	TTGP7BY	moderate	Biomarker	[139]
MARCKS	TTHRM39	moderate	Genetic Variation	[140]
NTF4	TTIM2WO	moderate	Biomarker	[141]
NTRK3	TTXABCW	moderate	Altered Expression	[142]
PCYT1B	TTUAIKM	moderate	Biomarker	[143]
PHGDH	TT8DRCK	moderate	Biomarker	[144]
PPIA	TTL2ADK	moderate	Biomarker	[145]
PTGER2	TT1ZAVI	moderate	Altered Expression	[146]
SGCG	TTSMT9W	moderate	Biomarker	[147]
SLC1A3	TT8WRDA	moderate	Genetic Variation	[148]
SNAP25	TTYQWA0	moderate	Biomarker	[149]
SRR	TTZFUY6	moderate	Altered Expression	[150]
TDP1	TT64IHJ	moderate	Biomarker	[151]
TRPM2	TTEBMN7	moderate	Genetic Variation	[152]
UCHL1	TTX9IFP	moderate	Biomarker	[153]
UCP3	TT12RJK	moderate	Altered Expression	[154]
UTRN	TTNO1VA	moderate	Genetic Variation	[155]
ADCYAP1	TTW4LYC	Strong	Biomarker	[156]
AIF1	TT12MEP	Strong	Biomarker	[157]
ANPEP	TTPHMWB	Strong	Altered Expression	[158]
APP	TTE4KHA	Strong	Altered Expression	[159]
ASPA	TT6TLZP	Strong	Biomarker	[103]
ATXN3	TT6A17J	Strong	Genetic Variation	[160]
BCL2L1	TTRE6AX	Strong	Biomarker	[41]
C3	TTJGY7A	Strong	Biomarker	[103]
C5AR1	TTHXFA1	Strong	Altered Expression	[161]
CAPN2	TTG5QB7	Strong	Altered Expression	[162]
CASP1	TTCQIBE	Strong	Biomarker	[163]
CASP9	TTB6T7O	Strong	Biomarker	[164]
CDK5R1	TTBYM6V	Strong	Biomarker	[165]
CHIT1	TTDYX6T	Strong	Biomarker	[64]
CNR2	TTMSFAW	Strong	Genetic Variation	[166]
CS	TTZA6B3	Strong	Biomarker	[144]
CX3CR1	TT2T98G	Strong	Biomarker	[167]
ERN1	TTKIAT3	Strong	Altered Expression	[168]
GAPDH	TTUGSWA	Strong	Altered Expression	[54]
GDNF	TTF23ML	Strong	Biomarker	[169]
GPNMB	TT7315J	Strong	Biomarker	[170]
GRIA1	TTVPQTF	Strong	Biomarker	[171]
GRM5	TTHS256	Strong	Altered Expression	[172]
HNRNPA1	TTPJ9XK	Strong	Biomarker	[173]
HSF1	TTN6STZ	Strong	Altered Expression	[174]
HSPB8	TTY0OJN	Strong	Biomarker	[175]
IGF1R	TTQFBMY	Strong	ModifyingMutation	[176]
IGF2R	TTPNE41	Strong	Biomarker	[177]
IL2RB	TT9721Y	Strong	Biomarker	[178]
KCNJ10	TTG140O	Strong	Biomarker	[179]
KEAP1	TT3Z6Y9	Strong	Genetic Variation	[180]
KHDRBS1	TTAT6C7	Strong	Genetic Variation	[180]
KIF5A	TTCJPAH	Strong	Genetic Variation	[181]
LGALS1	TTO3NYT	Strong	Genetic Variation	[182]
MAP2K5	TTV3O87	Strong	Biomarker	[183]
MAPT	TTS87KH	Strong	Biomarker	[123]
MOBP	TTYUK4F	Strong	Genetic Variation	[184]
MSMB	TTYH1ZK	Strong	Biomarker	[185]
MSTN	TTM8I2X	Strong	Biomarker	[186]
NEK1	TTO5QT2	Strong	Genetic Variation	[187]
NME9	TTHSVK0	Strong	Genetic Variation	[188]
NPEPPS	TT371QC	Strong	Genetic Variation	[189]
NRG1	TTEH395	Strong	Biomarker	[190]
NTF3	TTZHKV9	Strong	Biomarker	[191]
P2RX4	TT1NLOA	Strong	Biomarker	[192]
PIGL	TTQA8DT	Strong	Genetic Variation	[188]
PLCB1	TTLPGU7	Strong	Genetic Variation	[193]
PNPLA6	TTWAQU2	Strong	Biomarker	[194]
PRMT1	TTVOJAI	Strong	Biomarker	[195]
PRNP	TTY5F9C	Strong	Biomarker	[196]
PSIP1	TTH9LDP	Strong	Biomarker	[178]
PTBP1	TTWMX0U	Strong	Genetic Variation	[197]
PTGS2	TTVKILB	Strong	Biomarker	[47]
PTPRZ1	TT4SEA8	Strong	Therapeutic	[198]
RARA	TTW38KT	Strong	Biomarker	[199]
RIPK1	TTVJHX8	Strong	Biomarker	[200]
RNASEL	TT7V0K4	Strong	Genetic Variation	[201]
RRM1	TTWP0NS	Strong	Biomarker	[202]
RRM2	TT1S4LJ	Strong	Biomarker	[203]
RTN4	TT7GXMU	Strong	Altered Expression	[204]
S100A6	TT716MY	Strong	Biomarker	[205]
SCGB1A1	TTONPVW	Strong	Altered Expression	[206]
SCN8A	TT54ERL	Strong	Genetic Variation	[207]
SEMA3A	TTVKD3S	Strong	Altered Expression	[208]
SIGMAR1	TT5TPI6	Strong	Biomarker	[209]
SIRT2	TTLKF5M	Strong	Biomarker	[210]
SLC1A1	TTG2A6F	Strong	Biomarker	[211]
STK36	TTX5KEQ	Strong	Genetic Variation	[212]
STMN1	TT7W5OT	Strong	Biomarker	[213]
TBK1	TTMP03S	Strong	Biomarker	[214]
TCF3	TTULOD8	Strong	Biomarker	[178]
TGM2	TT2F4OL	Strong	Genetic Variation	[215]
TIAM1	TTNU6I5	Strong	Genetic Variation	[216]
TNFRSF1B	TT63WSF	Strong	Biomarker	[178]
TUSC2	TTJ8O14	Strong	Genetic Variation	[217]
UNC13B	TT948FC	Strong	Genetic Variation	[218]
VDAC1	TTAMKGB	Strong	Biomarker	[219]
FUS	TTKGYZ9	Definitive	Autosomal dominant	[220]
GJD2	TTOZAFI	Definitive	Biomarker	[221]
ITPR1	TT5HWAT	Definitive	Genetic Variation	[222]
ITPR3	TTH1769	Definitive	Genetic Variation	[222]
LANCL1	TTZW8NS	Definitive	Biomarker	[223]
MAP4K4	TT6NI13	Definitive	Biomarker	[224]
PSEN1	TTZ3S8C	Definitive	Genetic Variation	[225]
SOD2	TT9O4C5	Definitive	Biomarker	[226]
UCP1	TTI12YJ	Definitive	Biomarker	[227]
------------------------------------------------------------------------------------


⏷ Show the Full List of 220 DTT(s)

This Disease Is Related to 11 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
ANXA11	DTGQ2CF	Limited	Genetic Variation	[228]
ATP7A	DT0LT17	Limited	Genetic Variation	[229]
KCNK2	DTENHUP	Limited	Biomarker	[230]
SLC12A2	DTHKL3Q	Limited	Genetic Variation	[100]
SLC30A6	DTKPRIL	Limited	Genetic Variation	[231]
SLC8A3	DTYFRQT	Limited	Biomarker	[232]
ANXA11	DTGQ2CF	Supportive	Autosomal dominant	[233]
SLC17A6	DT5LHCR	moderate	Biomarker	[234]
SLC25A37	DTLBGTZ	moderate	Biomarker	[235]
SLC35A1	DTVZIRG	moderate	Biomarker	[236]
SLC52A3	DTBVQIO	moderate	Biomarker	[237]
------------------------------------------------------------------------------------


⏷ Show the Full List of 11 DTP(s)

This Disease Is Related to 20 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
ADH5	DEIOH6A	Limited	Biomarker	[238]
ALDH1A2	DEKN1H4	Limited	Altered Expression	[239]
EGLN3	DEMQTKH	Limited	Altered Expression	[240]
FMO3	DEP76YL	Limited	Altered Expression	[241]
MT1A	DE5ME8A	Limited	Altered Expression	[242]
SI	DE5EO4Y	Limited	Altered Expression	[83]
TGM6	DEUWCVD	Limited	Biomarker	[243]
PON1	DESDN74	Supportive	Autosomal dominant	[244]
PON2	DEHJU7E	Supportive	Autosomal dominant	[244]
PON3	DETXQZ1	Supportive	Autosomal dominant	[244]
SOD1	DEUTDON	Supportive	Autosomal dominant	[31]
CRMP1	DE0EUXB	moderate	Genetic Variation	[155]
DAO	DERZQ2Y	Moderate	Autosomal dominant	[135]
FMO1	DEJ73Q9	moderate	Altered Expression	[241]
NAT10	DEZV4AP	moderate	Biomarker	[123]
CYP27A1	DEBS639	Strong	Biomarker	[245]
FXN	DEXVHDB	Strong	Biomarker	[246]
GLS	DE3E0VT	Strong	Biomarker	[247]
PON2	DEHJU7E	Strong	GermlineCausalMutation	[118]
PON3	DETXQZ1	Strong	GermlineCausalMutation	[118]
------------------------------------------------------------------------------------


⏷ Show the Full List of 20 DME(s)

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
3	Pioglitazone FDA Label
4	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2326).
5	FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 215887.
6	ClinicalTrials.gov (NCT00069186) Study of Creatine Monohydrate in Patients With Amyotrophic Lateral Sclerosis. U.S. National Institutes of Health.
7	ClinicalTrials.gov (NCT00372879) Randomized Crossover Design Trial of Vitamin E vs Placebo for Treatment of Cramps in Amyotrophic Lateral Sclerosis. U.S.National Institutes of Health.
8	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9	ClinicalTrials.gov (NCT02039401) Safety Study of VM202 to Treat Amyotrophic Lateral Sclerosis. U.S. National Institutes of Health.
10	Clinical pipeline report, company report or official report of GlaxoSmithKline
11	ClinicalTrials.gov (NCT04768972) A Phase 1-3 Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Intrathecally Administered ION363 in Amyotrophic Lateral Sclerosis Patients With Fused in Sarcoma Mutations (FUS-ALS). U.S.National Institutes of Health.
12	ClinicalTrials.gov (NCT04322149) A Phase 2a Open-Label, Multi-Center Study to Evaluate the Safety and Tolerability of Multiple Doses of AT-1501 in Adults With ALS. U.S.National Institutes of Health.
13	ClinicalTrials.gov (NCT04494256) A Phase 1/2 Multiple-Ascending-Dose Study With a Long-Term Open-Label Extension to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Effect on Disease Progression of BIIB105 Administered Intrathecally to Adults With Amyotrophic Lateral Sclerosis With or Without Poly-CAG Expansion in the ATXN2 Gene. U.S.National Institutes of Health.
14	ClinicalTrials.gov (NCT04066244) Study of Safety and of the Mechanism of BLZ945 in ALS Patients. U.S. National Institutes of Health.
15	ClinicalTrials.gov (NCT05407324) A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Safety and Efficacy of CORT113176 (Dazucorilant) in Patients With Amyotrophic Lateral Sclerosis (DAZALS). U.S.National Institutes of Health.
16	Clinical pipeline report, company report or official report of Ionis Pharmaceuticals.
17	ClinicalTrials.gov (NCT01281631) A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS). U.S. National Institutes of Health.
18	ClinicalTrials.gov (NCT00002114) A Double-Blind, Randomized Parallel Group Study Comparing Procysteine to Placebo in HIV-Infected Patients Who Are Taking Antiretroviral Nucleosides. U.S. National Institutes of Health.
19	ClinicalTrials.gov (NCT03456882) The Effect of RNS60 on ALS Biomarkers (RNS60). U.S. National Institutes of Health.
20	ClinicalTrials.gov (NCT05237284) A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of SAR443820 in Adult Participants With Amyotrophic Lateral Sclerosis, Followed by an Open-label Extension. U.S.National Institutes of Health.
21	Bimoclomol: a nontoxic, hydroxylamine derivative with stress protein-inducing activity and cytoprotective effects. Nat Med. 1997 Oct;3(10):1150-4.
22	ClinicalTrials.gov (NCT03049046) CC100: Phase 1 Multiple-Dose Safety and Tolerability in Subjects With ALS (CC100B). U.S. National Institutes of Health.
23	ClinicalTrials.gov (NCT03757351) Study to Evaluate DNL747 in Subjects With Amyotrophic Lateral Sclerosis. U.S. National Institutes of Health.
24	Clinical pipeline report, company report or official report of ISIS Pharmaceuticals (2011).
25	ClinicalTrials.gov (NCT03954600) A Phase 1, Randomized, Double-Blind, Single and Multiple Ascending Dose Trial of the Safety, Tolerability and Pharmacokinetics of NPT520-34 in Healthy Subjects. U.S.National Institutes of Health.
26	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800003896)
27	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800020123)
28	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800002000)
29	Therapeutic targeting of the NRF2 and KEAP1 partnership in chronic diseases. Nat Rev Drug Discov. 2019 Apr;18(4):295-317.
30	Amyotrophic lateral sclerosis: an update on recent genetic insights. J Neurol. 2013 Nov;260(11):2917-27. doi: 10.1007/s00415-013-7112-y. Epub 2013 Oct 2.
31	Amyotrophic Lateral Sclerosis Overview. 2001 Mar 23 [updated 2023 Sep 28]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Bean LJH, Gripp KW, Amemiya A, editors. GeneReviews(?) [Internet]. Seattle (WA): University of Washington, Seattle; 1993C2024.
32	Dysfunction of endocytic kinase AAK1 in ALS.Int J Mol Sci. 2014 Dec 10;15(12):22918-32. doi: 10.3390/ijms151222918.
33	K(ATP) Channel Expression and Genetic Polymorphisms Associated with Progression and Survival in Amyotrophic Lateral Sclerosis.Mol Neurobiol. 2018 Oct;55(10):7962-7972. doi: 10.1007/s12035-018-0970-7. Epub 2018 Feb 28.
34	Astrocyte adenosine deaminase loss increases motor neuron toxicity in amyotrophic lateral sclerosis.Brain. 2019 Mar 1;142(3):586-605. doi: 10.1093/brain/awy353.
35	ADAMTS-4 in central nervous system pathologies.J Neurosci Res. 2017 Sep;95(9):1703-1711. doi: 10.1002/jnr.24021. Epub 2017 Jan 13.
36	PACAP and PAC1R are differentially expressed in motor cortex of amyotrophic lateral sclerosis patients and support survival of iPSC-derived motor neurons.J Cell Physiol. 2018 Apr;233(4):3343-3351. doi: 10.1002/jcp.26182. Epub 2017 Oct 20.
37	The motor unit number index (MUNIX) profile of patients with adult spinal muscular atrophy.Clin Neurophysiol. 2018 Nov;129(11):2333-2340. doi: 10.1016/j.clinph.2018.08.025. Epub 2018 Sep 13.
38	Phrenic long-term facilitation following intrapleural CTB-SAP-induced respiratory motor neuron death.Respir Physiol Neurobiol. 2018 Oct;256:43-49. doi: 10.1016/j.resp.2017.08.003. Epub 2017 Aug 16.
39	Classification of Genes: Standardized Clinical Validity Assessment of Gene-Disease Associations Aids Diagnostic Exome Analysis and Reclassifications. Hum Mutat. 2017 May;38(5):600-608. doi: 10.1002/humu.23183. Epub 2017 Feb 13.
40	Drosophila Ref1/ALYREF regulates transcription and toxicity associated with ALS/FTD disease etiologies.Acta Neuropathol Commun. 2019 Apr 29;7(1):65. doi: 10.1186/s40478-019-0710-x.
41	The BH4 domain of Bcl-X(L) rescues astrocyte degeneration in amyotrophic lateral sclerosis by modulating intracellular calcium signals.Hum Mol Genet. 2012 Feb 15;21(4):826-40. doi: 10.1093/hmg/ddr513. Epub 2011 Nov 9.
42	CACNA1H missense mutations associated with amyotrophic lateral sclerosis alter Cav3.2 T-type calcium channel activity and reticular thalamic neuron firing.Channels (Austin). 2016 Nov;10(6):466-77. doi: 10.1080/19336950.2016.1204497. Epub 2016 Jun 22.
43	Progressive muscle atrophy with hypokalemic periodic paralysis and calcium channel mutation.Muscle Nerve. 2008 Jan;37(1):120-4. doi: 10.1002/mus.20825.
44	A C9orf72-CARM1 axis regulates lipid metabolism under glucose starvation-induced nutrient stress.Genes Dev. 2018 Nov 1;32(21-22):1380-1397. doi: 10.1101/gad.315564.118. Epub 2018 Oct 26.
45	Extracellular TDP-43 aggregates target MAPK/MAK/MRK overlapping kinase (MOK) and trigger caspase-3/IL-18 signaling in microglia.FASEB J. 2017 Jul;31(7):2797-2816. doi: 10.1096/fj.201601163R. Epub 2017 Mar 23.
46	Technical standards for the interpretation and reporting of constitutional copy-number variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics (ACMG) and the Clinical Genome Resource (ClinGen). Genet Med. 2020 Feb;22(2):245-257. doi: 10.1038/s41436-019-0686-8. Epub 2019 Nov 6.
47	Increased Expression of 15-Hydroxyprostaglandin Dehydrogenase in Spinal Astrocytes During Disease Progression in a Model of Amyotrophic Lateral Sclerosis.Cell Mol Neurobiol. 2017 Apr;37(3):445-452. doi: 10.1007/s10571-016-0377-9. Epub 2016 May 2.
48	From transcriptome analysis to therapeutic anti-CD40L treatment in the SOD1 model of amyotrophic lateral sclerosis.Nat Genet. 2010 May;42(5):392-9. doi: 10.1038/ng.557. Epub 2010 Mar 28.
49	CDC7 inhibition blocks pathological TDP-43 phosphorylation and neurodegeneration.Ann Neurol. 2013 Jul;74(1):39-52. doi: 10.1002/ana.23870. Epub 2013 Jul 8.
50	Calpastatin inhibits motor neuron death and increases survival of hSOD1(G93A) mice.J Neurochem. 2016 Apr;137(2):253-65. doi: 10.1111/jnc.13536. Epub 2016 Mar 23.
51	Visual encoding, consolidation, and retrieval in amyotrophic lateral sclerosis: executive function as a mediator, and predictor of performance.Amyotroph Lateral Scler Frontotemporal Degener. 2017 May;18(3-4):193-201. doi: 10.1080/21678421.2016.1272615. Epub 2017 Jan 13.
52	CLEC4C p.K210del variant causes impaired cell surface transport in plasmacytoid dendritic cells of amyotrophic lateral sclerosis.Oncotarget. 2016 May 3;7(18):24942-9. doi: 10.18632/oncotarget.7886.
53	DDX3 binding with CK1 was closely related to motor neuron degeneration of ALS by affecting neurite outgrowth.Am J Transl Res. 2017 Oct 15;9(10):4627-4639. eCollection 2017.
54	Specific Physical Exercise Improves Energetic Metabolism in the Skeletal Muscle of Amyotrophic-Lateral- Sclerosis Mice.Front Mol Neurosci. 2017 Oct 20;10:332. doi: 10.3389/fnmol.2017.00332. eCollection 2017.
55	Overexpression of the essential Sis1 chaperone reduces TDP-43 effects on toxicity and proteolysis.PLoS Genet. 2017 May 22;13(5):e1006805. doi: 10.1371/journal.pgen.1006805. eCollection 2017 May.
56	Hu antigen R (HuR) is a positive regulator of the RNA-binding proteins TDP-43 and FUS/TLS: implications for amyotrophic lateral sclerosis.J Biol Chem. 2014 Nov 14;289(46):31792-31804. doi: 10.1074/jbc.M114.573246. Epub 2014 Sep 19.
57	Decreased circulating ErbB4 ectodomain fragments as a read-out of impaired signaling function in amyotrophic lateral sclerosis.Neurobiol Dis. 2019 Apr;124:428-438. doi: 10.1016/j.nbd.2018.12.021. Epub 2018 Dec 27.
58	In vivo EPR pharmacokinetic evaluation of the redox status and the blood brain barrier permeability in the SOD1(G93A) ALS rat model.Free Radic Biol Med. 2017 Jul;108:258-269. doi: 10.1016/j.freeradbiomed.2017.03.034. Epub 2017 Mar 31.
59	Muscle Fibers Secrete FGFBP1 to Slow Degeneration of Neuromuscular Synapses during Aging and Progression of ALS.J Neurosci. 2017 Jan 4;37(1):70-82. doi: 10.1523/JNEUROSCI.2992-16.2016.
60	Modeling amyotrophic lateral sclerosis in pure human iPSc-derived motor neurons isolated by a novel FACS double selection technique.Neurobiol Dis. 2015 Oct;82:269-280. doi: 10.1016/j.nbd.2015.06.011. Epub 2015 Jun 21.
61	Elevated levels of ferritin in the cerebrospinal fluid of amyotrophic lateral sclerosis patients.Acta Neurol Scand. 2017 Aug;136(2):145-150. doi: 10.1111/ane.12708. Epub 2016 Nov 1.
62	Inhibition of -Glucocerebrosidase Activity Preserves Motor Unit Integrity in a Mouse Model of Amyotrophic Lateral Sclerosis.Sci Rep. 2017 Jul 12;7(1):5235. doi: 10.1038/s41598-017-05313-0.
63	Decreased glutathione levels cause overt motor neuron degeneration in hSOD1(WT) over-expressing mice.Exp Neurol. 2018 Apr;302:129-135. doi: 10.1016/j.expneurol.2018.01.004. Epub 2018 Jan 4.
64	Different neuroinflammatory profile in amyotrophic lateral sclerosis and frontotemporal dementia is linked to the clinical phase.J Neurol Neurosurg Psychiatry. 2019 Jan;90(1):4-10. doi: 10.1136/jnnp-2018-318868. Epub 2018 Sep 17.
65	Postsynaptic alteration of NR2A subunit and defective autophosphorylation of alphaCaMKII at threonine-286 contribute to abnormal plasticity and morphology of upper motor neurons in presymptomatic SOD1G93A mice, a murine model for amyotrophic lateral sclerosis.Cereb Cortex. 2011 Apr;21(4):796-805. doi: 10.1093/cercor/bhq152. Epub 2010 Aug 23.
66	In-vivo genetic ablation of metabotropic glutamate receptor type 5 slows down disease progression in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis.Neurobiol Dis. 2019 Sep;129:79-92. doi: 10.1016/j.nbd.2019.05.007. Epub 2019 May 15.
67	Activation of mGlu3 metabotropic glutamate receptors enhances GDNF and GLT-1 formation in the spinal cord and rescues motor neurons in the SOD-1 mouse model of amyotrophic lateral sclerosis.Neurobiol Dis. 2015 Feb;74:126-36. doi: 10.1016/j.nbd.2014.11.012. Epub 2014 Nov 28.
68	Immunoglobulins G from Sera of Amyotrophic Lateral Sclerosis Patients Induce Oxidative Stress and Upregulation of Antioxidative System in BV-2 Microglial Cell Line.Front Immunol. 2017 Nov 23;8:1619. doi: 10.3389/fimmu.2017.01619. eCollection 2017.
69	Activity and expression of glutathione S-transferase pi in patients with amyotrophic lateral sclerosis.Clin Chim Acta. 2006 Feb;364(1-2):217-21. doi: 10.1016/j.cccn.2005.07.008. Epub 2005 Aug 18.
70	Synthesis and human/bacterial carbonic anhydrase inhibition with a series of sulfonamides incorporating phthalimido moieties.Bioorg Med Chem. 2017 Apr 15;25(8):2524-2529. doi: 10.1016/j.bmc.2017.03.017. Epub 2017 Mar 9.
71	Differential histone deacetylase mRNA expression patterns in amyotrophic lateral sclerosis.J Neuropathol Exp Neurol. 2010 Jun;69(6):573-81. doi: 10.1097/NEN.0b013e3181ddd404.
72	Medical conditions in Ashkenazi schizophrenic pedigrees.Schizophr Bull. 1994;20(3):507-17. doi: 10.1093/schbul/20.3.507.
73	Determining the Effect of the HNMT, STK39, and NMD3 Polymorphisms on the Incidence of Parkinson's Disease, Amyotrophic Lateral Sclerosis, and Multiple System Atrophy in Chinese Populations.J Mol Neurosci. 2018 Apr;64(4):574-580. doi: 10.1007/s12031-018-1048-8. Epub 2018 Mar 21.
74	Post-transcriptional Inhibition of Hsc70-4/HSPA8 Expression Leads to Synaptic Vesicle Cycling Defects in Multiple Models of ALS.Cell Rep. 2017 Oct 3;21(1):110-125. doi: 10.1016/j.celrep.2017.09.028.
75	Conditional deletion of Id2 or Notch1 in oligodendrocyte progenitor cells does not ameliorate disease outcome in SOD1(G93A) mice.Neurobiol Aging. 2018 Aug;68:1-4. doi: 10.1016/j.neurobiolaging.2018.03.026. Epub 2018 Apr 3.
76	FUS is sequestered in nuclear aggregates in ALS patient fibroblasts.Mol Biol Cell. 2014 Sep 1;25(17):2571-8. doi: 10.1091/mbc.E14-05-1007. Epub 2014 Jul 9.
77	An ALS-Associated Mutant SOD1 Rapidly Suppresses KCNT1 (Slack) Na(+)-Activated K(+) Channels in Aplysia Neurons.J Neurosci. 2017 Feb 22;37(8):2258-2265. doi: 10.1523/JNEUROSCI.3102-16.2017. Epub 2017 Jan 24.
78	L3MBTL1 regulates ALS/FTD-associated proteotoxicity and quality control.Nat Neurosci. 2019 Jun;22(6):875-886. doi: 10.1038/s41593-019-0384-5. Epub 2019 May 6.
79	IFN triggers a LIGHT-dependent selective death of motoneurons contributing to the non-cell-autonomous effects of mutant SOD1.Cell Death Differ. 2011 May;18(5):754-68. doi: 10.1038/cdd.2010.143. Epub 2010 Nov 12.
80	Genome-wide copy number variation in sporadic amyotrophic lateral sclerosis in the Turkish population: deletion of EPHA3 is a possible protective factor.PLoS One. 2013 Aug 26;8(8):e72381. doi: 10.1371/journal.pone.0072381. eCollection 2013.
81	Genetic induction of hypometabolism by ablation of MC4R does not suppress ALS-like phenotypes in the G93A mutant SOD1 mouse model.Sci Rep. 2017 Oct 13;7(1):13150. doi: 10.1038/s41598-017-13304-4.
82	The activation of Mucolipin TRP channel 1 (TRPML1) protects motor neurons from L-BMAA neurotoxicity by promoting autophagic clearance.Sci Rep. 2019 Jul 24;9(1):10743. doi: 10.1038/s41598-019-46708-5.
83	Metabolic signatures of amyotrophic lateral sclerosis reveal insights into disease pathogenesis.Proc Natl Acad Sci U S A. 2013 Jun 25;110(26):10812-7. doi: 10.1073/pnas.1308421110. Epub 2013 Jun 10.
84	Single-Cell Analysis of SMN Reveals Its Broader Role in Neuromuscular Disease.Cell Rep. 2017 Feb 7;18(6):1484-1498. doi: 10.1016/j.celrep.2017.01.035.
85	Strong P2X4 purinergic receptor-like immunoreactivity is selectively associated with degenerating neurons in transgenic rodent models of amyotrophic lateral sclerosis.J Comp Neurol. 2008 Jan 1;506(1):75-92. doi: 10.1002/cne.21527.
86	P2X7 activation enhances skeletal muscle metabolism and regeneration in SOD1G93A mouse model of amyotrophic lateral sclerosis.Brain Pathol. 2020 Mar;30(2):272-282. doi: 10.1111/bpa.12774. Epub 2019 Aug 18.
87	Histamine Regulates the Inflammatory Profile of SOD1-G93A Microglia and the Histaminergic System Is Dysregulated in Amyotrophic Lateral Sclerosis.Front Immunol. 2017 Nov 30;8:1689. doi: 10.3389/fimmu.2017.01689. eCollection 2017.
88	Poly-A binding protein-1 localization to a subset of TDP-43 inclusions in amyotrophic lateral sclerosis occurs more frequently in patients harboring an expansion in C9orf72.J Neuropathol Exp Neurol. 2014 Sep;73(9):837-45. doi: 10.1097/NEN.0000000000000102.
89	Phenylalanine hydroxylase: A biomarker of disease susceptibility in Parkinson's disease and Amyotrophic lateral sclerosis.Med Hypotheses. 2018 Sep;118:29-33. doi: 10.1016/j.mehy.2018.06.018. Epub 2018 Jun 20.
90	A high-density genome-wide association screen of sporadic ALS in US veterans.PLoS One. 2012;7(3):e32768. doi: 10.1371/journal.pone.0032768. Epub 2012 Mar 28.
91	Deregulation of PKN1 activity disrupts neurofilament organisation and axonal transport.FEBS Lett. 2008 Jun 25;582(15):2303-2308. doi: 10.1016/j.febslet.2008.05.034. Epub 2008 Jun 2.
92	Integrative role of cPLA with COX-2 and the effect of non-steriodal anti-inflammatory drugs in a transgenic mouse model of amyotrophic lateral sclerosis.J Neurochem. 2005 Apr;93(2):403-11. doi: 10.1111/j.1471-4159.2005.03024.x.
93	Disruption of skeletal muscle mitochondrial network genes and miRNAs in amyotrophic lateral sclerosis.Neurobiol Dis. 2013 Jan;49:107-17. doi: 10.1016/j.nbd.2012.08.015. Epub 2012 Sep 4.
94	Enhancing mitochondrial calcium buffering capacity reduces aggregation of misfolded SOD1 and motor neuron cell death without extending survival in mouse models of inherited amyotrophic lateral sclerosis.J Neurosci. 2013 Mar 13;33(11):4657-71. doi: 10.1523/JNEUROSCI.1119-12.2013.
95	A Possible Role for Platelet-Activating Factor Receptor in Amyotrophic Lateral Sclerosis Treatment.Front Neurol. 2018 Feb 6;9:39. doi: 10.3389/fneur.2018.00039. eCollection 2018.
96	Characterization of Motor Neuron Prostaglandin E2 EP3 Receptor Isoform in a Mouse Model of Amyotrophic Lateral Sclerosis.Biol Pharm Bull. 2015;38(12):1964-8. doi: 10.1248/bpb.b15-00418.
97	Two potential biomarkers identified in mesenchymal stem cells and leukocytes of patients with sporadic amyotrophic lateral sclerosis.Dis Markers. 2012;32(4):211-20. doi: 10.3233/DMA-2011-0885.
98	Differential sirtuin expression patterns in amyotrophic lateral sclerosis (ALS) postmortem tissue: neuroprotective or neurotoxic properties of sirtuins in ALS?.Neurodegener Dis. 2013;11(3):141-52. doi: 10.1159/000338048. Epub 2012 Jul 10.
99	Association between divalent metal transport 1 encoding gene (SLC11A2) and disease duration in amyotrophic lateral sclerosis.J Neurol Sci. 2011 Apr 15;303(1-2):124-7. doi: 10.1016/j.jns.2010.12.018. Epub 2011 Jan 26.
100	Downregulation of the potassium chloride cotransporter KCC2 in vulnerable motoneurons in the SOD1-G93A mouse model of amyotrophic lateral sclerosis.J Neuropathol Exp Neurol. 2010 Oct;69(10):1057-70. doi: 10.1097/NEN.0b013e3181f4dcef.
101	The acetyl-CoA transporter family SLC33.Mol Aspects Med. 2013 Apr-Jun;34(2-3):586-9. doi: 10.1016/j.mam.2012.05.009.
102	Changes in skeletal muscle iron metabolism outpace amyotrophic lateral sclerosis onset in transgenic rats bearing the G93A hmSOD1 gene mutation.Free Radic Res. 2014 Nov;48(11):1363-70. doi: 10.3109/10715762.2014.955484. Epub 2014 Sep 11.
103	In vitro activation of GAT1 transporters expressed in spinal cord gliosomes stimulates glutamate release that is abnormally elevated in the SOD1/G93A(+) mouse model of amyotrophic lateral sclerosis.J Neurochem. 2010 Apr;113(2):489-501. doi: 10.1111/j.1471-4159.2010.06628.x. Epub 2010 Feb 1.
104	System xC- is a mediator of microglial function and its deletion slows symptoms in amyotrophic lateral sclerosis mice.Brain. 2015 Jan;138(Pt 1):53-68. doi: 10.1093/brain/awu312. Epub 2014 Nov 10.
105	Analysis of the SORT1 gene in familial amyotrophic lateral sclerosis.Neurobiol Aging. 2012 Aug;33(8):1845.e7-9. doi: 10.1016/j.neurobiolaging.2012.01.011. Epub 2012 Feb 22.
106	Silencing of the Drosophila ortholog of SOX5 leads to abnormal neuronal development and behavioral impairment.Hum Mol Genet. 2017 Apr 15;26(8):1472-1482. doi: 10.1093/hmg/ddx051.
107	Innate immune adaptor TRIF deficiency accelerates disease progression of ALS mice with accumulation of aberrantly activated astrocytes.Cell Death Differ. 2018 Dec;25(12):2130-2146. doi: 10.1038/s41418-018-0098-3. Epub 2018 Mar 22.
108	Death receptor 6 (DR6) antagonist antibody is neuroprotective in the mouse SOD1G93A model of amyotrophic lateral sclerosis.Cell Death Dis. 2013 Oct 10;4(10):e841. doi: 10.1038/cddis.2013.378.
109	Poly(ADP-Ribose) Prevents Pathological Phase Separation of TDP-43 by Promoting Liquid Demixing and Stress Granule Localization.Mol Cell. 2018 Sep 6;71(5):703-717.e9. doi: 10.1016/j.molcel.2018.07.002. Epub 2018 Aug 9.
110	Degeneration of serotonin neurons triggers spasticity in amyotrophic lateral sclerosis.Ann Neurol. 2017 Sep;82(3):444-456. doi: 10.1002/ana.25030.
111	The tau tubulin kinases TTBK1/2 promote accumulation of pathological TDP-43.PLoS Genet. 2014 Dec 4;10(12):e1004803. doi: 10.1371/journal.pgen.1004803. eCollection 2014 Dec.
112	The essential and downstream common proteins of amyotrophic lateral sclerosis: A protein-protein interaction network analysis.PLoS One. 2017 Mar 10;12(3):e0172246. doi: 10.1371/journal.pone.0172246. eCollection 2017.
113	Amyotrophic lateral sclerosis and denervation alter sphingolipids and up-regulate glucosylceramide synthase.Hum Mol Genet. 2015 Dec 20;24(25):7390-405. doi: 10.1093/hmg/ddv439. Epub 2015 Oct 19.
114	Recapitulation of Pathological TDP-43 Features in Immortalized Lymphocytes from Sporadic ALS Patients.Mol Neurobiol. 2019 Apr;56(4):2424-2432. doi: 10.1007/s12035-018-1249-8. Epub 2018 Jul 20.
115	Cross-sectional and longitudinal assessment of the upper cervical spinal cord in motor neuron disease.Neuroimage Clin. 2019;24:101984. doi: 10.1016/j.nicl.2019.101984. Epub 2019 Aug 16.
116	Inhibition of collapsin response mediator protein-2 phosphorylation ameliorates motor phenotype of ALS model mice expressing SOD1G93A.Neurosci Res. 2019 Feb;139:63-68. doi: 10.1016/j.neures.2018.08.016. Epub 2018 Sep 5.
117	Elevated serum creatine kinase in the early stage of sporadic amyotrophic lateral sclerosis.J Neurol. 2019 Dec;266(12):2952-2961. doi: 10.1007/s00415-019-09507-6. Epub 2019 Aug 27.
118	Genetics of amyotrophic lateral sclerosis: an update. Mol Neurodegener. 2013 Aug 13;8:28. doi: 10.1186/1750-1326-8-28.
119	ERBB4 mutations that disrupt the neuregulin-ErbB4 pathway cause amyotrophic lateral sclerosis type 19. Am J Hum Genet. 2013 Nov 7;93(5):900-5. doi: 10.1016/j.ajhg.2013.09.008. Epub 2013 Oct 10.
120	Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause multisystem proteinopathy and ALS. Nature. 2013 Mar 28;495(7442):467-73. doi: 10.1038/nature11922. Epub 2013 Mar 3.
121	Mutations in the gene encoding p62 in Japanese patients with amyotrophic lateral sclerosis. Neurology. 2013 Jan 29;80(5):458-63. doi: 10.1212/WNL.0b013e31827f0fe5. Epub 2013 Jan 9.
122	Specific induction of Akt3 in spinal cord motor neurons is neuroprotective in a mouse model of familial amyotrophic lateral sclerosis.Mol Neurobiol. 2014 Feb;49(1):136-48. doi: 10.1007/s12035-013-8507-6. Epub 2013 Jul 20.
123	The cargo receptor SQSTM1 ameliorates neurofibrillary tangle pathology and spreading through selective targeting of pathological MAPT (microtubule associated protein tau).Autophagy. 2019 Apr;15(4):583-598. doi: 10.1080/15548627.2018.1532258. Epub 2018 Oct 16.
124	Upregulation of ATG7 attenuates motor neuron dysfunction associated with depletion of TARDBP/TDP-43.Autophagy. 2020 Apr;16(4):672-682. doi: 10.1080/15548627.2019.1635379. Epub 2019 Jul 7.
125	Localization of the gene for the ciliary neurotrophic factor receptor (CNTFR) to human chromosome 9.Genomics. 1993 Sep;17(3):782-4. doi: 10.1006/geno.1993.1409.
126	Protective effects of cardiotrophin-1 adenoviral gene transfer on neuromuscular degeneration in transgenic ALS mice.Hum Mol Genet. 2001 Sep 1;10(18):1925-33. doi: 10.1093/hmg/10.18.1925.
127	Focus on the role of D-serine and D-amino acid oxidase in amyotrophic lateral sclerosis/motor neuron disease (ALS). Front Mol Biosci. 2018 Feb 13;5:8.
128	PKR activation in neurodegenerative disease.J Neuropathol Exp Neurol. 2004 Feb;63(2):97-105. doi: 10.1093/jnen/63.2.97.
129	Ephexin1 Is Required for Eph-Mediated Limb Trajectory of Spinal Motor Axons.J Neurosci. 2018 Feb 21;38(8):2043-2056. doi: 10.1523/JNEUROSCI.2257-17.2018. Epub 2018 Jan 23.
130	Characterization of FUS mutations in amyotrophic lateral sclerosis using RNA-Seq.PLoS One. 2013;8(4):e60788. doi: 10.1371/journal.pone.0060788. Epub 2013 Apr 8.
131	Differential expression of 14 genes in amyotrophic lateral sclerosis spinal cord detected using gridded cDNA arrays.J Neurochem. 2001 Apr;77(1):132-45. doi: 10.1046/j.1471-4159.2001.t01-1-00231.x.
132	Flip and flop splice variants of AMPA receptor subunits in the spinal cord of amyotrophic lateral sclerosis.Synapse. 2002 Sep 15;45(4):245-9. doi: 10.1002/syn.10098.
133	The gene encoding the glutamate receptor subunit GluR5 is located on human chromosome 21q21.1-22.1 in the vicinity of the gene for familial amyotrophic lateral sclerosis.Proc Natl Acad Sci U S A. 1993 Jan 1;90(1):178-82. doi: 10.1073/pnas.90.1.178.
134	Heme oxygenase in the experimental ALS mouse.Exp Neurol. 1998 Apr;150(2):206-12. doi: 10.1006/exnr.1997.6763.
135	The Gene Curation Coalition: A global effort to harmonize gene-disease evidence resources. Genet Med. 2022 Aug;24(8):1732-1742. doi: 10.1016/j.gim.2022.04.017. Epub 2022 May 4.
136	Mechanistic View of hnRNPA2 Low-Complexity Domain Structure, Interactions, and Phase Separation Altered by Mutation and Arginine Methylation.Mol Cell. 2018 Feb 1;69(3):465-479.e7. doi: 10.1016/j.molcel.2017.12.022. Epub 2018 Jan 18.
137	ITPR2 as a susceptibility gene in sporadic amyotrophic lateral sclerosis: a genome-wide association study.Lancet Neurol. 2007 Oct;6(10):869-77. doi: 10.1016/S1474-4422(07)70222-3.
138	Investigation of MGF mRNA expression in patients with amyotrophic lateral sclerosis using parallel in vivo and in vitro approaches.Amyotroph Lateral Scler. 2010;11(1-2):172-7. doi: 10.3109/17482960903089775.
139	Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial.Muscle Nerve. 2019 Feb;59(2):201-207. doi: 10.1002/mus.26335. Epub 2018 Nov 26.
140	Increased phospho-adducin immunoreactivity in a murine model of amyotrophic lateral sclerosis.Neuroscience. 2005;134(3):833-46. doi: 10.1016/j.neuroscience.2005.04.036.
141	Elevated levels of neurotrophins in human biceps brachii tissue of amyotrophic lateral sclerosis.Exp Neurol. 2002 Oct;177(2):419-27. doi: 10.1006/exnr.2002.8011.
142	Neurotrophin-3-like immunoreactivity and Trk C expression in human spinal motoneurones in amyotrophic lateral sclerosis.J Neurol Sci. 1997 May 1;148(1):33-40. doi: 10.1016/s0022-510x(96)00312-7.
143	Hypoglossal Motor Neuron Death Via Intralingual CTB-saporin (CTB-SAP) Injections Mimic Aspects of Amyotrophic Lateral Sclerosis (ALS) Related to Dysphagia.Neuroscience. 2018 Oct 15;390:303-316. doi: 10.1016/j.neuroscience.2018.08.026. Epub 2018 Sep 1.
144	Swim Training Modulates Mouse Skeletal Muscle Energy Metabolism and Ameliorates Reduction in Grip Strength in a Mouse Model of Amyotrophic Lateral Sclerosis.Int J Mol Sci. 2019 Jan 9;20(2):233. doi: 10.3390/ijms20020233.
145	Targeting Extracellular Cyclophilin A Reduces Neuroinflammation and Extends Survival in a Mouse Model of Amyotrophic Lateral Sclerosis.J Neurosci. 2017 Feb 8;37(6):1413-1427. doi: 10.1523/JNEUROSCI.2462-16.2016. Epub 2016 Dec 23.
146	Pathophysiological role of prostaglandin E2-induced up-regulation of the EP2 receptor in motor neuron-like NSC-34 cells and lumbar motor neurons in ALS model mice.Neurochem Int. 2018 Oct;119:132-139. doi: 10.1016/j.neuint.2017.06.013. Epub 2017 Jul 4.
147	Rab-dependent cellular trafficking and amyotrophic lateral sclerosis.Crit Rev Biochem Mol Biol. 2018 Dec;53(6):623-651. doi: 10.1080/10409238.2018.1553926.
148	GLT-1 glutamate transporter levels are unchanged in mice expressing G93A human mutant SOD1.J Neurol Sci. 2002 Jan 15;193(2):117-26. doi: 10.1016/s0022-510x(01)00656-6.
149	Overview of Impaired BDNF Signaling, Their Coupled Downstream Serine-Threonine Kinases and SNARE/SM Complex in the Neuromuscular Junction of the Amyotrophic Lateral Sclerosis Model SOD1-G93A Mice.Mol Neurobiol. 2019 Oct;56(10):6856-6872. doi: 10.1007/s12035-019-1550-1. Epub 2019 Mar 30.
150	Paradoxical roles of serine racemase and D-serine in the G93A mSOD1 mouse model of amyotrophic lateral sclerosis.J Neurochem. 2012 Feb;120(4):598-610. doi: 10.1111/j.1471-4159.2011.07601.x. Epub 2012 Jan 4.
151	The Caenorhabditis elegans Ortholog of TDP-43 Regulates the Chromatin Localization of the Heterochromatin Protein 1 Homolog HPL-2.Mol Cell Biol. 2018 Jul 16;38(15):e00668-17. doi: 10.1128/MCB.00668-17. Print 2018 Aug 1.
152	Altered functional properties of a TRPM2 variant in Guamanian ALS and PD.Proc Natl Acad Sci U S A. 2008 Nov 18;105(46):18029-34. doi: 10.1073/pnas.0808218105. Epub 2008 Nov 12.
153	Targeted Multiple Reaction Monitoring Analysis of CSF Identifies UCHL1 and GPNMB as Candidate Biomarkers for ALS.J Mol Neurosci. 2019 Dec;69(4):643-657. doi: 10.1007/s12031-019-01411-y. Epub 2019 Nov 12.
154	Up-regulation of mitochondrial uncoupling protein 3 reveals an early muscular metabolic defect in amyotrophic lateral sclerosis.FASEB J. 2003 Nov;17(14):2091-3. doi: 10.1096/fj.02-1182fje. Epub 2003 Sep 18.
155	Inhibition of Drp1/Fis1 interaction slows progression of amyotrophic lateral sclerosis.EMBO Mol Med. 2018 Mar;10(3):e8166. doi: 10.15252/emmm.201708166.
156	Molecular mechanisms involved in the protective effect of pituitary adenylate cyclase-activating polypeptide in an in vitro model of amyotrophic lateral sclerosis.J Cell Physiol. 2019 Apr;234(4):5203-5214. doi: 10.1002/jcp.27328. Epub 2018 Sep 21.
157	TSPO Versus P2X7 as a Target for Neuroinflammation: An In Vitro and In Vivo Study.J Nucl Med. 2020 Apr;61(4):604-607. doi: 10.2967/jnumed.119.231985. Epub 2019 Sep 27.
158	Adiponectin levels in the serum and cerebrospinal fluid of amyotrophic lateral sclerosis patients: possible influence on neuroinflammation?.J Neuroinflammation. 2017 Apr 20;14(1):85. doi: 10.1186/s12974-017-0861-2.
159	CSF sAPP, YKL-40, and NfL along the ALS-FTD spectrum.Neurology. 2018 Oct 23;91(17):e1619-e1628. doi: 10.1212/WNL.0000000000006383. Epub 2018 Oct 5.
160	Genome-wide Analyses Identify KIF5A as a Novel ALS Gene.Neuron. 2018 Mar 21;97(6):1267-1288. doi: 10.1016/j.neuron.2018.02.027.
161	Complement components are upregulated and correlate with disease progression in the TDP-43(Q331K) mouse model of amyotrophic lateral sclerosis.J Neuroinflammation. 2018 Jun 1;15(1):171. doi: 10.1186/s12974-018-1217-2.
162	Expression of three calpain isoform genes in human skeletal muscles.J Neurol Sci. 1998 Mar 5;155(2):163-9. doi: 10.1016/s0022-510x(97)00309-2.
163	The microglial NLRP3 inflammasome is activated by amyotrophic lateral sclerosis proteins.Glia. 2020 Feb;68(2):407-421. doi: 10.1002/glia.23728. Epub 2019 Oct 9.
164	Induction of the unfolded protein response in familial amyotrophic lateral sclerosis and association of protein-disulfide isomerase with superoxide dismutase 1.J Biol Chem. 2006 Oct 6;281(40):30152-65. doi: 10.1074/jbc.M603393200. Epub 2006 Jul 17.
165	Sensory cortex hyperexcitability predicts short survival in amyotrophic lateral sclerosis.Neurology. 2018 May 1;90(18):e1578-e1587. doi: 10.1212/WNL.0000000000005424. Epub 2018 Mar 30.
166	Changes in endocannabinoid receptors and enzymes in the spinal cord of SOD1(G93A) transgenic mice and evaluation of a Sativex() -like combination of phytocannabinoids: interest for future therapies in amyotrophic lateral sclerosis.CNS Neurosci Ther. 2014 Sep;20(9):809-15. doi: 10.1111/cns.12262. Epub 2014 Apr 7.
167	Evidence for a protective role of the CX3CL1/CX3CR1 axis in a model of amyotrophic lateral sclerosis.Biol Chem. 2019 Apr 24;400(5):651-661. doi: 10.1515/hsz-2018-0204.
168	Amyotrophic lateral sclerosis (ALS) and Alzheimer's disease (AD) are characterised by differential activation of ER stress pathways: focus on UPR target genes.Cell Stress Chaperones. 2018 Sep;23(5):897-912. doi: 10.1007/s12192-018-0897-y. Epub 2018 May 4.
169	Triple-Gene Therapy for Stroke: A Proof-of-Concept in Vivo Study in Rats.Front Pharmacol. 2018 Feb 15;9:111. doi: 10.3389/fphar.2018.00111. eCollection 2018.
170	Proteomics in cerebrospinal fluid and spinal cord suggests UCHL1, MAP2 and GPNMB as biomarkers and underpins importance of transcriptional pathways in amyotrophic lateral sclerosis.Acta Neuropathol. 2020 Jan;139(1):119-134. doi: 10.1007/s00401-019-02093-x. Epub 2019 Nov 7.
171	Interferon- Receptor 1 and GluR1 upregulated in motor neurons of symptomatic hSOD1G93A mice.Eur J Neurosci. 2019 Jan;49(1):62-78. doi: 10.1111/ejn.14276. Epub 2018 Dec 27.
172	Metabotropic glutamate receptor subtype 5 is altered in LPS-induced murine neuroinflammation model and in the brains of AD and ALS patients.Eur J Nucl Med Mol Imaging. 2019 Feb;46(2):407-420. doi: 10.1007/s00259-018-4179-9. Epub 2018 Oct 5.
173	PARylation regulates stress granule dynamics, phase separation, and neurotoxicity of disease-related RNA-binding proteins.Cell Res. 2019 Mar;29(3):233-247. doi: 10.1038/s41422-019-0141-z. Epub 2019 Feb 6.
174	Dipeptide repeat proteins activate a heat shock response found in C9ORF72-ALS/FTLD patients.Acta Neuropathol Commun. 2018 Jul 4;6(1):55. doi: 10.1186/s40478-018-0555-8.
175	Proteostasis and ALS: protocol for a phase II, randomised, double-blind, placebo-controlled, multicentre clinical trial for colchicine in ALS (Co-ALS).BMJ Open. 2019 May 30;9(5):e028486. doi: 10.1136/bmjopen-2018-028486.
176	Transcriptional profile of primary astrocytes expressing ALS-linked mutant SOD1.J Neurosci Res. 2008 Dec;86(16):3515-25. doi: 10.1002/jnr.21797.
177	Up-regulation of insulin-like growth factor-II receptor in reactive astrocytes in the spinal cord of amyotrophic lateral sclerosis transgenic rats.Tohoku J Exp Med. 2008 Apr;214(4):303-10. doi: 10.1620/tjem.214.303.
178	Urinary p75(ECD): A prognostic, disease progression, and pharmacodynamic biomarker in ALS.Neurology. 2017 Mar 21;88(12):1137-1143. doi: 10.1212/WNL.0000000000003741. Epub 2017 Feb 22.
179	Changes in the astrocytic aquaporin-4 and inwardly rectifying potassium channel expression in the brain of the amyotrophic lateral sclerosis SOD1(G93A) rat model.Glia. 2012 Dec;60(12):1991-2003. doi: 10.1002/glia.22414. Epub 2012 Sep 14.
180	An FTLD-associated SQSTM1 variant impacts Nrf2 and NF-B signalling and is associated with reduced phosphorylation of p62.Mol Cell Neurosci. 2019 Jul;98:32-45. doi: 10.1016/j.mcn.2019.04.001. Epub 2019 Apr 4.
181	Mutation analysis of KIF5A in Chinese amyotrophic lateral sclerosis patients.Neurobiol Aging. 2019 Jan;73:229.e1-229.e4. doi: 10.1016/j.neurobiolaging.2018.08.006. Epub 2018 Aug 9.
182	Galectin-1 deficiency improves axonal swelling of motor neurones in SOD1(G93A) transgenic mice.Neuropathol Appl Neurobiol. 2015 Feb;41(2):227-44. doi: 10.1111/nan.12123.
183	Inhibition of MEK5 suppresses TDP-43 toxicity via the mTOR-independent activation of the autophagy-lysosome pathway.Biochem Biophys Res Commun. 2019 Jun 11;513(4):925-932. doi: 10.1016/j.bbrc.2019.04.088. Epub 2019 Apr 17.
184	Genome-wide association analyses identify new risk variants and the genetic architecture of amyotrophic lateral sclerosis. Nat Genet. 2016 Sep;48(9):1043-8. doi: 10.1038/ng.3622. Epub 2016 Jul 25.
185	VAMP associated proteins are required for autophagic and lysosomal degradation by promoting a PtdIns4P-mediated endosomal pathway.Autophagy. 2019 Jul;15(7):1214-1233. doi: 10.1080/15548627.2019.1580103. Epub 2019 Feb 20.
186	Myostatin inhibition slows muscle atrophy in rodent models of amyotrophic lateral sclerosis.Neurobiol Dis. 2006 Sep;23(3):697-707. doi: 10.1016/j.nbd.2006.05.009. Epub 2006 Jul 11.
187	Rare homozygosity in amyotrophic lateral sclerosis suggests the contribution of recessive variants to disease genetics.J Neurol Sci. 2019 Jul 15;402:62-68. doi: 10.1016/j.jns.2019.05.006. Epub 2019 May 8.
188	C9orf72 and UNC13A are shared risk loci for amyotrophic lateral sclerosis and frontotemporal dementia: a genome-wide meta-analysis.Ann Neurol. 2014 Jul;76(1):120-33. doi: 10.1002/ana.24198. Epub 2014 Jun 27.
189	No evidence for shared genetic basis of common variants in multiple sclerosis and amyotrophic lateral sclerosis.Hum Mol Genet. 2014 Apr 1;23(7):1916-22. doi: 10.1093/hmg/ddt574. Epub 2013 Nov 13.
190	Neuregulin 1 Reduces Motoneuron Cell Death and Promotes Neurite Growth in an in Vitro Model of Motoneuron Degeneration.Front Cell Neurosci. 2018 Jan 9;11:431. doi: 10.3389/fncel.2017.00431. eCollection 2017.
191	NurOwn, phase 2, randomized, clinical trial in patients with ALS: Safety, clinical, and biomarker results.Neurology. 2019 Dec 10;93(24):e2294-e2305. doi: 10.1212/WNL.0000000000008620. Epub 2019 Nov 18.
192	Immunodetection of disease-associated conformers of mutant cu/zn superoxide dismutase 1 selectively expressed in degenerating neurons in amyotrophic lateral sclerosis.J Neuropathol Exp Neurol. 2013 Jul;72(7):646-61. doi: 10.1097/NEN.0b013e318297fd10.
193	De novo single-nucleotide and copy number variation in discordant monozygotic twins reveals disease-related genes. Eur J Hum Genet. 2019 Jul;27(7):1121-1133. doi: 10.1038/s41431-019-0376-7. Epub 2019 Mar 18.
194	Neuropathy target esterase gene mutations cause motor neuron disease. Am J Hum Genet. 2008 Mar;82(3):780-5. doi: 10.1016/j.ajhg.2007.12.018. Epub 2008 Feb 28.
195	Increase of arginine dimethylation correlates with the progression and prognosis of ALS.Neurology. 2019 Apr 16;92(16):e1868-e1877. doi: 10.1212/WNL.0000000000007311. Epub 2019 Mar 13.
196	Prion-like mechanisms in amyotrophic lateral sclerosis.Handb Clin Neurol. 2018;153:337-354. doi: 10.1016/B978-0-444-63945-5.00018-0.
197	Single-copy expression of an amyotrophic lateral sclerosis-linked TDP-43 mutation (M337V) in BAC transgenic mice leads to altered stress granule dynamics and progressive motor dysfunction.Neurobiol Dis. 2019 Jan;121:148-162. doi: 10.1016/j.nbd.2018.09.024. Epub 2018 Oct 2.
198	Intrathecal delivery of mesenchymal stromal cells protects the structure of altered perineuronal nets in SOD1 rats and amends the course of ALS.Stem Cells. 2014 Dec;32(12):3163-72. doi: 10.1002/stem.1812.
199	Retinoid receptors in chronic degeneration of the spinal cord: observations in a rat model of amyotrophic lateral sclerosis.J Neurochem. 2007 Dec;103(5):1821-33. doi: 10.1111/j.1471-4159.2007.04893.x. Epub 2007 Sep 13.
200	Multitasking Kinase RIPK1 Regulates Cell Death and Inflammation.Cold Spring Harb Perspect Biol. 2020 Mar 2;12(3):a036368. doi: 10.1101/cshperspect.a036368.
201	Insights into the role of ribonuclease 4 polymorphisms in amyotrophic lateral sclerosis.J Biomol Struct Dyn. 2019 Jan;37(1):116-130. doi: 10.1080/07391102.2017.1419147. Epub 2018 Jan 7.
202	Virus-mediated delivery of antibody targeting TAR DNA-binding protein-43 mitigates associated neuropathology.J Clin Invest. 2019 Feb 25;129(4):1581-1595. doi: 10.1172/JCI123931. eCollection 2019 Feb 25.
203	Small Molecule Targeting TDP-43's RNA Recognition Motifs Reduces Locomotor Defects in a Drosophila Model of Amyotrophic Lateral Sclerosis (ALS).ACS Chem Biol. 2019 Sep 20;14(9):2006-2013. doi: 10.1021/acschembio.9b00481. Epub 2019 Aug 27.
204	Conditional Overexpression of rtn4al in Muscle of Adult Zebrafish Displays Defects Similar to Human Amyotrophic Lateral Sclerosis.Mar Biotechnol (NY). 2019 Feb;21(1):52-64. doi: 10.1007/s10126-018-9857-x. Epub 2018 Nov 15.
205	Astrocytic calcium/zinc binding protein S100A6 over expression in Alzheimer's disease and in PS1/APP transgenic mice models.Biochim Biophys Acta. 2004 Dec 6;1742(1-3):161-8. doi: 10.1016/j.bbamcr.2004.09.011.
206	Plasma level of club-cell (CC-16) predicts outcome in amyotrophic lateral sclerosis.Acta Neurol Scand. 2018 Feb;137(2):233-237. doi: 10.1111/ane.12851. Epub 2017 Oct 1.
207	Genome-wide genotyping in amyotrophic lateral sclerosis and neurologically normal controls: first stage analysis and public release of data.Lancet Neurol. 2007 Apr;6(4):322-8. doi: 10.1016/S1474-4422(07)70037-6.
208	ALS-related human cortical and motor neurons survival is differentially affected by Sema3A.Cell Death Dis. 2018 Feb 15;9(3):256. doi: 10.1038/s41419-018-0294-6.
209	Sigma-1 receptor is a key genetic modulator in amyotrophic lateral sclerosis.Hum Mol Genet. 2020 Mar 13;29(4):529-540. doi: 10.1093/hmg/ddz267.
210	Review of the anti-inflammatory effect of SIRT1 and SIRT2 modulators on neurodegenerative diseases.Eur J Pharmacol. 2020 Jan 15;867:172847. doi: 10.1016/j.ejphar.2019.172847. Epub 2019 Dec 5.
211	Edaravone suppresses retinal ganglion cell death in a mouse model of normal tension glaucoma.Cell Death Dis. 2017 Jul 13;8(7):e2934. doi: 10.1038/cddis.2017.341.
212	Age of onset of amyotrophic lateral sclerosis is modulated by a locus on 1p34.1.Neurobiol Aging. 2013 Jan;34(1):357.e7-19. doi: 10.1016/j.neurobiolaging.2012.07.017. Epub 2012 Sep 5.
213	The Actin Cytoskeleton in SMA and ALS: How Does It Contribute to Motoneuron Degeneration?.Neuroscientist. 2018 Feb;24(1):54-72. doi: 10.1177/1073858417705059. Epub 2017 May 1.
214	Retinoic acid worsens ATG10-dependent autophagy impairment in TBK1-mutant hiPSC-derived motoneurons through SQSTM1/p62 accumulation.Autophagy. 2019 Oct;15(10):1719-1737. doi: 10.1080/15548627.2019.1589257. Epub 2019 Apr 2.
215	New insight into transglutaminase 2 and link to neurodegenerative diseases.BMB Rep. 2018 Jan;51(1):5-13. doi: 10.5483/bmbrep.2018.51.1.227.
216	Chromosome 9p21 in amyotrophic lateral sclerosis in Finland: a genome-wide association study.Lancet Neurol. 2010 Oct;9(10):978-85. doi: 10.1016/S1474-4422(10)70184-8.
217	Vascular regression precedes motor neuron loss in the FUS (1-359) ALS mouse model.Dis Model Mech. 2019 Aug 13;12(8):dmm040238. doi: 10.1242/dmm.040238.
218	Molecular Mechanisms Linking ALS/FTD and Psychiatric Disorders, the Potential Effects of Lithium.Front Cell Neurosci. 2019 Oct 4;13:450. doi: 10.3389/fncel.2019.00450. eCollection 2019.
219	A VDAC1-Derived N-Terminal Peptide Inhibits Mutant SOD1-VDAC1 Interactions and Toxicity in the SOD1 Model of ALS.Front Cell Neurosci. 2019 Aug 14;13:346. doi: 10.3389/fncel.2019.00346. eCollection 2019.
220	De novo FUS mutations in 2 Korean patients with sporadic amyotrophic lateral sclerosis. Neurobiol Aging. 2015 Mar;36(3):1604.e17-9. doi: 10.1016/j.neurobiolaging.2014.10.002. Epub 2014 Oct 13.
221	A potential role for neuronal connexin 36 in the pathogenesis of amyotrophic lateral sclerosis.Neurosci Lett. 2018 Feb 14;666:1-4. doi: 10.1016/j.neulet.2017.12.027. Epub 2017 Dec 12.
222	Genetic analyses uncover pleiotropic compensatory roles for Drosophila Nucleobindin-1 in inositol trisphosphate-mediated intracellular calcium homeostasis.Genome. 2020 Feb;63(2):61-90. doi: 10.1139/gen-2019-0113. Epub 2019 Sep 26.
223	LanCL1 promotes motor neuron survival and extends the lifespan of amyotrophic lateral sclerosis mice.Cell Death Differ. 2020 Apr;27(4):1369-1382. doi: 10.1038/s41418-019-0422-6. Epub 2019 Sep 30.
224	MAP4K4 Activation Mediates Motor Neuron Degeneration in Amyotrophic Lateral Sclerosis.Cell Rep. 2019 Jan 29;26(5):1143-1156.e5. doi: 10.1016/j.celrep.2019.01.019.
225	Mutation analysis of patients with neurodegenerative disorders using NeuroX array.Neurobiol Aging. 2015 Jan;36(1):545.e9-14. doi: 10.1016/j.neurobiolaging.2014.07.038. Epub 2014 Aug 1.
226	Mutation analyses in amyotrophic lateral sclerosis/parkinsonism-dementia complex of the Kii peninsula, Japan.Mov Disord. 2008 Dec 15;23(16):2344-8. doi: 10.1002/mds.22262.
227	Histone deacetylase 4 protects from denervation and skeletal muscle atrophy in a murine model of amyotrophic lateral sclerosis.EBioMedicine. 2019 Feb;40:717-732. doi: 10.1016/j.ebiom.2019.01.038. Epub 2019 Feb 1.
228	Two rare variants of the ANXA11 gene identified in Chinese patients with amyotrophic lateral sclerosis.Neurobiol Aging. 2019 Feb;74:235.e9-235.e12. doi: 10.1016/j.neurobiolaging.2018.09.020. Epub 2018 Sep 22.
229	Altered intracellular localization and valosin-containing protein (p97 VCP) interaction underlie ATP7A-related distal motor neuropathy.Hum Mol Genet. 2012 Apr 15;21(8):1794-807. doi: 10.1093/hmg/ddr612. Epub 2011 Dec 30.
230	Endothelial TWIK-related potassium channel-1 (TREK1) regulates immune-cell trafficking into the CNS.Nat Med. 2013 Sep;19(9):1161-5. doi: 10.1038/nm.3303. Epub 2013 Aug 11.
231	Zinc transporters ZnT3 and ZnT6 are downregulated in the spinal cords of patients with sporadic amyotrophic lateral sclerosis.J Neurosci Res. 2015 Feb;93(2):370-9. doi: 10.1002/jnr.23491. Epub 2014 Oct 3.
232	Preconditioning, induced by sub-toxic dose of the neurotoxin L-BMAA, delays ALS progression in mice and prevents Na(+)/Ca(2+) exchanger 3 downregulation.Cell Death Dis. 2018 Feb 12;9(2):206. doi: 10.1038/s41419-017-0227-9.
233	Mutations in the vesicular trafficking protein annexin A11 are associated with amyotrophic lateral sclerosis. Sci Transl Med. 2017 May 3;9(388):eaad9157. doi: 10.1126/scitranslmed.aad9157.
234	Differential involvement of vesicular and glial glutamate transporters around spinal -motoneurons in the pathogenesis of SOD1(G93A) mouse model of amyotrophic lateral sclerosis.Neuroscience. 2017 Jul 25;356:114-124. doi: 10.1016/j.neuroscience.2017.05.014. Epub 2017 May 17.
235	Reduced sirtuin 1/adenosine monophosphate-activated protein kinase in amyotrophic lateral sclerosis patient-derived mesenchymal stem cells can be restored by resveratrol.J Tissue Eng Regen Med. 2019 Jan;13(1):110-115. doi: 10.1002/term.2776. Epub 2018 Dec 10.
236	The same cortico-efferent tract involvement in progressive bulbar palsy and in 'classical' ALS: A tract of interest-based MRI study.Neuroimage Clin. 2019;24:101979. doi: 10.1016/j.nicl.2019.101979. Epub 2019 Aug 9.
237	Mutation screening of SLC52A3, C19orf12, and TARDBP in Iranian ALS patients.Neurobiol Aging. 2019 Mar;75:225.e9-225.e14. doi: 10.1016/j.neurobiolaging.2018.11.003. Epub 2018 Nov 16.
238	nNOS/GSNOR interaction contributes to skeletal muscle differentiation and homeostasis.Cell Death Dis. 2019 May 1;10(5):354. doi: 10.1038/s41419-019-1584-3.
239	Aldehyde Dehydrogenases 1A2 Expression and Distribution are Potentially Associated with Neuron Death in Spinal Cord of Tg(SOD1*G93A)1Gur Mice.Int J Biol Sci. 2017 Apr 10;13(5):574-587. doi: 10.7150/ijbs.19150. eCollection 2017.
240	Impaired hypoxic sensor Siah-1, PHD3, and FIH system in spinal motor neurons of an amyotrophic lateral sclerosis mouse model.J Neurosci Res. 2013 Feb;91(2):285-91. doi: 10.1002/jnr.23129. Epub 2012 Nov 14.
241	Flavin-containing monooxygenase mRNA levels are up-regulated in als brain areas in SOD1-mutant mice.Neurotox Res. 2011 Aug;20(2):150-8. doi: 10.1007/s12640-010-9230-y. Epub 2010 Nov 17.
242	Overexpression of metallothionein-I, a copper-regulating protein, attenuates intracellular copper dyshomeostasis and extends lifespan in a mouse model of amyotrophic lateral sclerosis caused by mutant superoxide dismutase-1.Hum Mol Genet. 2014 Mar 1;23(5):1271-85. doi: 10.1093/hmg/ddt517. Epub 2013 Oct 24.
243	Transglutaminase 6 Antibodies in the Serum of Patients With Amyotrophic Lateral Sclerosis.JAMA Neurol. 2015 Jun;72(6):676-81. doi: 10.1001/jamaneurol.2015.48.
244	Paraoxonase gene mutations in amyotrophic lateral sclerosis. Ann Neurol. 2010 Jul;68(1):102-7. doi: 10.1002/ana.21993.
245	Cholesterol, oxysterol, triglyceride, and coenzyme Q homeostasis in ALS. Evidence against the hypothesis that elevated 27-hydroxycholesterol is a pathogenic factor.PLoS One. 2014 Nov 21;9(11):e113619. doi: 10.1371/journal.pone.0113619. eCollection 2014.
246	Diagnostics and Treatments of Iron-Related CNS Diseases.Adv Exp Med Biol. 2019;1173:179-194. doi: 10.1007/978-981-13-9589-5_10.
247	Serial deletion reveals structural basis and stability for the core enzyme activity of human glutaminase 1 isoforms: relevance to excitotoxic neurodegeneration.Transl Neurodegener. 2017 Apr 20;6:10. doi: 10.1186/s40035-017-0080-x. eCollection 2017.
248	GAB(A) receptors present higher affinity and modified subunit composition in spinal motor neurons from a genetic model of amyotrophic lateral sclerosis.Eur J Neurosci. 2008 Oct;28(7):1275-85. doi: 10.1111/j.1460-9568.2008.06436.x.
249	Metabolic Reprogramming in Amyotrophic Lateral Sclerosis.Sci Rep. 2018 Mar 2;8(1):3953. doi: 10.1038/s41598-018-22318-5.
250	Differential gene expression in patients with amyotrophic lateral sclerosis.Amyotroph Lateral Scler. 2011 Jul;12(4):250-6. doi: 10.3109/17482968.2011.560946. Epub 2011 Mar 4.
251	Characterization of Parkinson's disease using blood-based biomarkers: A multicohort proteomic analysis.PLoS Med. 2019 Oct 11;16(10):e1002931. doi: 10.1371/journal.pmed.1002931. eCollection 2019 Oct.
252	Profound downregulation of the RNA editing enzyme ADAR2 in ALS spinal motor neurons.Neurobiol Dis. 2012 Mar;45(3):1121-8. doi: 10.1016/j.nbd.2011.12.033. Epub 2011 Dec 28.
253	Enzymatically inactive adenylate kinase 4 interacts with mitochondrial ADP/ATP translocase.Int J Biochem Cell Biol. 2009 Jun;41(6):1371-80. doi: 10.1016/j.biocel.2008.12.002. Epub 2008 Dec 14.
254	Exocytosis regulates trafficking of GABA and glycine heterotransporters in spinal cord glutamatergic synapses: a mechanism for the excessive heterotransporter-induced release of glutamate in experimental amyotrophic lateral sclerosis.Neurobiol Dis. 2015 Feb;74:314-24. doi: 10.1016/j.nbd.2014.12.004. Epub 2014 Dec 10.
255	Cytoplasmic mislocalization of RNA splicing factors and aberrant neuronal gene splicing in TDP-43 transgenic pig brain.Mol Neurodegener. 2015 Sep 3;10:42. doi: 10.1186/s13024-015-0036-5.
256	The potential roles of aquaporin 4 in amyotrophic lateral sclerosis.Neurol Sci. 2019 Aug;40(8):1541-1549. doi: 10.1007/s10072-019-03877-5. Epub 2019 Apr 13.
257	Associative Increases in Amyotrophic Lateral Sclerosis Survival Duration With Non-invasive Ventilation Initiation and Usage Protocols.Front Neurol. 2018 Jul 12;9:578. doi: 10.3389/fneur.2018.00578. eCollection 2018.
258	Cryptic exon splicing function of TARDBP interacts with autophagy in nervous tissue.Autophagy. 2018;14(8):1398-1403. doi: 10.1080/15548627.2018.1474311. Epub 2018 Jul 28.
259	Complex phenotype in an Italian family with a novel mutation in SPG3A.J Neurol. 2010 Mar;257(3):328-31. doi: 10.1007/s00415-009-5311-3. Epub 2009 Sep 19.
260	C9ORF72-ALS/FTD-associated poly(GR) binds Atp5a1 and compromises mitochondrial function in vivo.Nat Neurosci. 2019 Jun;22(6):851-862. doi: 10.1038/s41593-019-0397-0. Epub 2019 May 13.
261	Validation of qPCR reference genes in lymphocytes from patients with amyotrophic lateral sclerosis.PLoS One. 2017 Mar 22;12(3):e0174317. doi: 10.1371/journal.pone.0174317. eCollection 2017.
262	Ultra-High Field Diffusion MRI Reveals Early Axonal Pathology in Spinal Cord of ALS mice.Transl Neurodegener. 2018 Aug 8;7:20. doi: 10.1186/s40035-018-0122-z. eCollection 2018.
263	Mutant SOD1 Increases APP Expression and Phosphorylation in Cellular and Animal Models of ALS.PLoS One. 2015 Nov 24;10(11):e0143420. doi: 10.1371/journal.pone.0143420. eCollection 2015.
264	Bcl11b: A New Piece to the Complex Puzzle of Amyotrophic Lateral Sclerosis Neuropathogenesis?.Neurotox Res. 2016 Feb;29(2):201-7. doi: 10.1007/s12640-015-9573-5. Epub 2015 Nov 12.
265	A novel mouse model with impaired dynein/dynactin function develops amyotrophic lateral sclerosis (ALS)-like features in motor neurons and improves lifespan in SOD1-ALS mice.Hum Mol Genet. 2008 Sep 15;17(18):2849-62. doi: 10.1093/hmg/ddn182. Epub 2008 Jun 25.
266	Developmentally Regulated RNA-binding Protein 1 (Drb1)/RNA-binding Motif Protein 45 (RBM45), a Nuclear-Cytoplasmic Trafficking Protein, Forms TAR DNA-binding Protein 43 (TDP-43)-mediated Cytoplasmic Aggregates.J Biol Chem. 2016 Jul 15;291(29):14996-5007. doi: 10.1074/jbc.M115.712232. Epub 2016 May 12.
267	Selective Genetic Overlap Between Amyotrophic Lateral Sclerosis and Diseases of the Frontotemporal Dementia Spectrum.JAMA Neurol. 2018 Jul 1;75(7):860-875. doi: 10.1001/jamaneurol.2018.0372.
268	The Bcl-2 Homology-3 Domain (BH3)-Only Proteins, Bid, DP5/Hrk, and BNip3L, Are Upregulated in Reactive Astrocytes of End-Stage Mutant SOD1 Mouse Spinal Cord.Front Cell Neurosci. 2018 Jan 30;12:15. doi: 10.3389/fncel.2018.00015. eCollection 2018.
269	A novel Akt/PKB-interacting protein promotes cell adhesion and inhibits familial amyotrophic lateral sclerosis-linked mutant SOD1-induced neuronal death via inhibition of PP2A-mediated dephosphorylation of Akt/PKB.Cell Signal. 2008 Mar;20(3):493-505. doi: 10.1016/j.cellsig.2007.11.004. Epub 2007 Nov 17.
270	Genome-wide association analyses in Han Chinese identify two new susceptibility loci for amyotrophic lateral sclerosis.Nat Genet. 2013 Jun;45(6):697-700. doi: 10.1038/ng.2627. Epub 2013 Apr 28.
271	Calretinin and Neuropeptide Y interneurons are differentially altered in the motor cortex of the SOD1(G93A) mouse model of ALS.Sci Rep. 2017 Mar 15;7:44461. doi: 10.1038/srep44461.
272	Calpain activation and CaMKIV reduction in spinal cords from hSOD1G93A mouse model.Mol Cell Neurosci. 2014 Jul;61:219-25. doi: 10.1016/j.mcn.2014.07.002. Epub 2014 Jul 22.
273	Increased cerebrospinal fluid levels of cytokines monocyte chemoattractant protein-1 (MCP-1) and macrophage inflammatory protein-1 (MIP-1) in patients with amyotrophic lateral sclerosis.Neurologia (Engl Ed). 2020 Apr;35(3):165-169. doi: 10.1016/j.nrl.2017.07.020. Epub 2017 Oct 11.
274	CMS-01 Genetic testing for familial amyotrophic lateral sclerosis (ALS): insights and challenges.Amyotroph Lateral Scler Frontotemporal Degener. 2019 Nov;20(sup1):327-347. doi: 10.1080/21678421.2019.1647002.
275	Human angiogenin is a neuroprotective factor and amyotrophic lateral sclerosis associated angiogenin variants affect neurite extension/pathfinding and survival of motor neurons.Hum Mol Genet. 2008 Jan 1;17(1):130-49. doi: 10.1093/hmg/ddm290. Epub 2007 Oct 4.
276	A data-driven approach links microglia to pathology and prognosis in amyotrophic lateral sclerosis.Acta Neuropathol Commun. 2017 Mar 16;5(1):23. doi: 10.1186/s40478-017-0424-x.
277	Ablation of keratan sulfate accelerates early phase pathogenesis of ALS.PLoS One. 2013 Jun 25;8(6):e66969. doi: 10.1371/journal.pone.0066969. Print 2013.
278	ALS-causing SOD1 mutants generate vascular changes prior to motor neuron degeneration.Nat Neurosci. 2008 Apr;11(4):420-2. doi: 10.1038/nn2073. Epub 2008 Mar 16.
279	ALS blood expression profiling identifies new biomarkers, patient subgroups, and evidence for neutrophilia and hypoxia.J Transl Med. 2019 May 22;17(1):170. doi: 10.1186/s12967-019-1909-0.
280	Resequencing of 29 candidate genes in patients with familial and sporadic amyotrophic lateral sclerosis.Arch Neurol. 2011 May;68(5):587-93. doi: 10.1001/archneurol.2010.351. Epub 2011 Jan 10.
281	Inhibition of RNA lariat debranching enzyme suppresses TDP-43 toxicity in ALS disease models.Nat Genet. 2012 Dec;44(12):1302-9. doi: 10.1038/ng.2434. Epub 2012 Oct 28.
282	The TGF- System As a Potential Pathogenic Player in Disease Modulation of Amyotrophic Lateral Sclerosis.Front Neurol. 2017 Dec 15;8:669. doi: 10.3389/fneur.2017.00669. eCollection 2017.
283	Reduction of ephrin-A5 aggravates disease progression in amyotrophic lateral sclerosis.Acta Neuropathol Commun. 2019 Jul 12;7(1):114. doi: 10.1186/s40478-019-0759-6.
284	A neuroprotective astrocyte state is induced by neuronal signal EphB1 but fails in ALS models.Nat Commun. 2017 Oct 27;8(1):1164. doi: 10.1038/s41467-017-01283-z.
285	Mutant FUS and ELAVL4 (HuD) Aberrant Crosstalk in Amyotrophic Lateral Sclerosis.Cell Rep. 2019 Jun 25;27(13):3818-3831.e5. doi: 10.1016/j.celrep.2019.05.085.
286	Systemic down-regulation of delta-9 desaturase promotes muscle oxidative metabolism and accelerates muscle function recovery following nerve injury.PLoS One. 2013 Jun 13;8(6):e64525. doi: 10.1371/journal.pone.0064525. Print 2013.
287	Repetitive Nerve Stimulation in Amyotrophic Lateral Sclerosis.Chin Med J (Engl). 2018 Sep 20;131(18):2146-2151. doi: 10.4103/0366-6999.240798.
288	Amyotrophic lateral sclerosis: The complement and inflammatory hypothesis.Mol Immunol. 2018 Oct;102:14-25. doi: 10.1016/j.molimm.2018.06.007. Epub 2018 Jun 20.
289	The roles of intrinsic disorder-based liquid-liquid phase transitions in the "Dr. Jekyll-Mr. Hyde" behavior of proteins involved in amyotrophic lateral sclerosis and frontotemporal lobar degeneration.Autophagy. 2017;13(12):2115-2162. doi: 10.1080/15548627.2017.1384889. Epub 2017 Dec 17.
290	Expression of Wnt5a and its receptor Fzd2 is changed in the spinal cord of adult amyotrophic lateral sclerosis transgenic mice.Int J Clin Exp Pathol. 2013 Jun 15;6(7):1245-60. Print 2013.
291	Cerebrospinal fluid from patients with amyotrophic lateral sclerosis inhibits sonic hedgehog function.PLoS One. 2017 Feb 7;12(2):e0171668. doi: 10.1371/journal.pone.0171668. eCollection 2017.
292	Sporadic amyotrophic lateral sclerosis: is SMN-Gemins protein complex of importance for the relative resistance of oculomotor nucleus motoneurons to degeneration?.Folia Neuropathol. 2018;56(4):308-320. doi: 10.5114/fn.2018.80864.
293	A Genome-wide Expression Association Analysis Identifies Genes and Pathways Associated with Amyotrophic Lateral Sclerosis.Cell Mol Neurobiol. 2018 Apr;38(3):635-639. doi: 10.1007/s10571-017-0512-2. Epub 2017 Jun 21.
294	Mutation analysis of GLT8D1 and ARPP21 genes in amyotrophic lateral sclerosis patients from mainland China.Neurobiol Aging. 2020 Jan;85:156.e1-156.e4. doi: 10.1016/j.neurobiolaging.2019.09.013. Epub 2019 Sep 25.
295	Communication Matters-Pitfalls and Promise of Hightech Communication Devices in Palliative Care of Severely Physically Disabled Patients With Amyotrophic Lateral Sclerosis.Front Neurol. 2018 Jul 27;9:603. doi: 10.3389/fneur.2018.00603. eCollection 2018.
296	Motoneuron-specific NR3B gene: no association with ALS and evidence for a common null allele.Neurology. 2008 Feb 26;70(9):666-76. doi: 10.1212/01.wnl.0000271078.51280.17. Epub 2007 Aug 8.
297	HLA-DRA/HLA-DRB5 polymorphism affects risk of sporadic ALS and survival in a southwest Chinese cohort.J Neurol Sci. 2017 Feb 15;373:124-128. doi: 10.1016/j.jns.2016.12.055. Epub 2016 Dec 28.
298	Major histocompatibility complex class I molecules protect motor neurons from astrocyte-induced toxicity in amyotrophic lateral sclerosis.Nat Med. 2016 Apr;22(4):397-403. doi: 10.1038/nm.4052. Epub 2016 Feb 29.
299	Genetic and Pathological Assessment of hnRNPA1, hnRNPA2/B1, and hnRNPA3 in Familial and Sporadic Amyotrophic Lateral Sclerosis.Neurodegener Dis. 2017;17(6):304-312. doi: 10.1159/000481258. Epub 2017 Nov 11.
300	Phosphorylation of hnRNP K by cyclin-dependent kinase 2 controls cytosolic accumulation of TDP-43.Hum Mol Genet. 2015 Mar 15;24(6):1655-69. doi: 10.1093/hmg/ddu578. Epub 2014 Nov 19.
301	Downregulation of Homer1b/c in SOD1 G93A Models of ALS: A Novel Mechanism of Neuroprotective Effect of Lithium and Valproic Acid.Int J Mol Sci. 2016 Dec 17;17(12):2129. doi: 10.3390/ijms17122129.
302	HtrA2/Omi-immunoreactive intraneuronal inclusions in the anterior horn of patients with sporadic and Cu/Zn superoxide dismutase (SOD1) mutant amyotrophic lateral sclerosis.Neuropathol Appl Neurobiol. 2010 Jun;36(4):331-44. doi: 10.1111/j.1365-2990.2010.01075.x. Epub 2010 Feb 25.
303	Genetic studies of GRN and IFT74 in amyotrophic lateral sclerosis.Neurobiol Aging. 2008 Aug;29(8):1279-82. doi: 10.1016/j.neurobiolaging.2007.02.022. Epub 2007 Mar 23.
304	Degeneration of axons in spinal white matter in G93A mSOD1 mouse characterized by NFL and -internexin immunoreactivity.Brain Res. 2012 Jul 17;1465:90-100. doi: 10.1016/j.brainres.2012.05.018. Epub 2012 May 17.
305	FIG4 variants in central European patients with amyotrophic lateral sclerosis: a whole-exome and targeted sequencing study.Eur J Hum Genet. 2017 Feb;25(3):324-331. doi: 10.1038/ejhg.2016.186. Epub 2017 Jan 4.
306	Effects of mutant TDP-43 on the Nrf2/ARE pathway and protein expression of MafK and JDP2 in NSC-34 cells.Genet Mol Res. 2017 May 10;16(2). doi: 10.4238/gmr16029638.
307	Evaluating noncoding nucleotide repeat expansions in amyotrophic lateral sclerosis.Neurobiol Aging. 2014 Apr;35(4):936.e1-4. doi: 10.1016/j.neurobiolaging.2013.09.024. Epub 2013 Oct 23.
308	Vorapaxar and Amyotrophic Lateral Sclerosis: Coincidence or Adverse Association?.Am J Ther. 2017 Mar/Apr;24(2):e139-e143. doi: 10.1097/MJT.0000000000000395.
309	Protein aggregation due to nsSNP resulting in P56S VABP protein is associated with amyotrophic lateral sclerosis.J Theor Biol. 2014 Aug 7;354:72-80. doi: 10.1016/j.jtbi.2014.03.027. Epub 2014 Mar 27.
310	Dexpramipexole as an oral steroid-sparing agent in hypereosinophilic syndromes.Blood. 2018 Aug 2;132(5):501-509. doi: 10.1182/blood-2018-02-835330. Epub 2018 May 8.
311	Selective overexpression of gamma1 laminin in astrocytes in amyotrophic lateral sclerosis indicates an involvement in ALS pathology.J Neurosci Res. 2007 Jul;85(9):2045-58. doi: 10.1002/jnr.21314.
312	Expression of human FUS protein in Drosophila leads to progressive neurodegeneration.Protein Cell. 2011 Jun;2(6):477-86. doi: 10.1007/s13238-011-1065-7. Epub 2011 Jul 12.
313	Cognitive correlates in amyotrophic lateral sclerosis: a population-based study in Italy.J Neurol Neurosurg Psychiatry. 2015 Feb;86(2):168-73. doi: 10.1136/jnnp-2013-307223. Epub 2014 Apr 25.
314	Spinocerebellar Ataxia Tethering PCR: A Rapid Genetic Test for the Diagnosis of Spinocerebellar Ataxia Types 1, 2, 3, 6, and 7 by PCR and Capillary Electrophoresis.J Mol Diagn. 2018 May;20(3):289-297. doi: 10.1016/j.jmoldx.2017.12.006. Epub 2018 Feb 17.
315	Futsch/MAP1B mRNA is a translational target of TDP-43 and is neuroprotective in a Drosophila model of amyotrophic lateral sclerosis.J Neurosci. 2014 Nov 26;34(48):15962-74. doi: 10.1523/JNEUROSCI.2526-14.2014.
316	Open-label 24-week extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis.Amyotroph Lateral Scler Frontotemporal Degener. 2017 Oct;18(sup1):55-63. doi: 10.1080/21678421.2017.1364269.
317	Gain of interaction of ALS-linked G93A superoxide dismutase with cytosolic malate dehydrogenase.Neurobiol Dis. 2008 Oct;32(1):133-41. doi: 10.1016/j.nbd.2008.06.010. Epub 2008 Jul 3.
318	Genetic testing and genetic counseling for amyotrophic lateral sclerosis: an update for clinicians.Genet Med. 2017 Mar;19(3):267-274. doi: 10.1038/gim.2016.107. Epub 2016 Aug 18.
319	MEF2D and MEF2C pathways disruption in sporadic and familial ALS patients.Mol Cell Neurosci. 2016 Jul;74:10-7. doi: 10.1016/j.mcn.2016.02.002. Epub 2016 Feb 24.
320	Mahogunin ring finger 1 confers cytoprotection against mutant SOD1 aggresomes and is defective in an ALS mouse model.Neurobiol Dis. 2016 Feb;86:16-28. doi: 10.1016/j.nbd.2015.11.017. Epub 2015 Nov 29.
321	Loss of Ranbp2 in motoneurons causes disruption of nucleocytoplasmic and chemokine signaling, proteostasis of hnRNPH3 and Mmp28, and development of amyotrophic lateral sclerosis-like syndromes.Dis Model Mech. 2017 May 1;10(5):559-579. doi: 10.1242/dmm.027730. Epub 2017 Jan 18.
322	Generation and characterization of transgenic mice expressing mitochondrial targeted red fluorescent protein selectively in neurons: modeling mitochondriopathy in excitotoxicity and amyotrophic lateral sclerosis.Mol Neurodegener. 2011 Nov 2;6:75. doi: 10.1186/1750-1326-6-75.
323	Increased expression of Myosin binding protein H in the skeletal muscle of amyotrophic lateral sclerosis patients.Biochim Biophys Acta. 2014 Jan;1842(1):99-106. doi: 10.1016/j.bbadis.2013.10.013. Epub 2013 Oct 30.
324	Defects in optineurin- and myosin VI-mediated cellular trafficking in amyotrophic lateral sclerosis.Hum Mol Genet. 2015 Jul 1;24(13):3830-46. doi: 10.1093/hmg/ddv126. Epub 2015 Apr 9.
325	Skeletal Muscle Remodelling as a Function of Disease Progression in Amyotrophic Lateral Sclerosis.Biomed Res Int. 2016;2016:5930621. doi: 10.1155/2016/5930621. Epub 2016 Apr 18.
326	miR126-5p Downregulation Facilitates Axon Degeneration and NMJ Disruption via a Non-Cell-Autonomous Mechanism in ALS.J Neurosci. 2018 Jun 13;38(24):5478-5494. doi: 10.1523/JNEUROSCI.3037-17.2018. Epub 2018 May 17.
327	Neural induction with neurogenin 1 enhances the therapeutic potential of mesenchymal stem cells in an amyotrophic lateral sclerosis mouse model.Cell Transplant. 2013;22(5):855-70. doi: 10.3727/096368912X637019.
328	Neuroprotective role of the basic leucine zipper transcription factor NFIL3 in models of amyotrophic lateral sclerosis.J Biol Chem. 2014 Jan 17;289(3):1629-38. doi: 10.1074/jbc.M113.524389. Epub 2013 Nov 26.
329	Non-Methylation-Linked Mechanism of REST-Induced Neuroglobin Expression Impacts Mitochondrial Phenotypes in a Mouse Model of Amyotrophic Lateral Sclerosis.Neuroscience. 2019 Aug 1;412:233-247. doi: 10.1016/j.neuroscience.2019.05.039. Epub 2019 May 31.
330	The predictive value of respiratory function tests for non-invasive ventilation in amyotrophic lateral sclerosis.Respir Res. 2017 Jul 25;18(1):144. doi: 10.1186/s12931-017-0624-8.
331	Proteomic analysis of exosome-enriched fractions derived from cerebrospinal fluid of amyotrophic lateral sclerosis patients.Neurosci Res. 2020 Nov;160:43-49. doi: 10.1016/j.neures.2019.10.010. Epub 2019 Oct 24.
332	Cerebral ischemia induces the aggregation of proteins linked to neurodegenerative diseases.Sci Rep. 2018 Feb 9;8(1):2701. doi: 10.1038/s41598-018-21063-z.
333	Distinct expression and regulation of the glutamate transporter isoforms GLT-1a and GLT-1b in cultured astrocytes from a rat model of amyotrophic lateral sclerosis (hSOD1G93A).Neurochem Int. 2009 Jul-Aug;55(1-3):28-34. doi: 10.1016/j.neuint.2009.02.003. Epub 2009 Feb 24.
334	Evaluation of NADPH oxidases as drug targets in a mouse model of familial amyotrophic lateral sclerosis.Free Radic Biol Med. 2016 Aug;97:95-108. doi: 10.1016/j.freeradbiomed.2016.05.016. Epub 2016 May 19.
335	Cerebrospinal fluid neurogranin concentration in neurodegeneration: relation to clinical phenotypes and neuropathology.Acta Neuropathol. 2018 Sep;136(3):363-376. doi: 10.1007/s00401-018-1851-x. Epub 2018 Apr 26.
336	mTh1 driven expression of hTDP-43 results in typical ALS/FTLD neuropathological symptoms.PLoS One. 2018 May 22;13(5):e0197674. doi: 10.1371/journal.pone.0197674. eCollection 2018.
337	Dynamic mislocalizations of nuclear pore complex proteins after focal cerebral ischemia in rat.J Neurosci Res. 2017 Sep;95(9):1745-1759. doi: 10.1002/jnr.24005. Epub 2016 Dec 28.
338	New insights into the gene expression associated to amyotrophic lateral sclerosis.Life Sci. 2018 Jan 15;193:110-123. doi: 10.1016/j.lfs.2017.12.016. Epub 2017 Dec 11.
339	Human motor neurons generated from neural stem cells delay clinical onset and prolong life in ALS mouse model.PLoS One. 2014 May 20;9(5):e97518. doi: 10.1371/journal.pone.0097518. eCollection 2014.
340	Oxysterol-binding protein ORP3 rescues the Amyotrophic Lateral Sclerosis-linked mutant VAPB phenotype.Exp Cell Res. 2016 Feb 1;341(1):18-31. doi: 10.1016/j.yexcr.2016.01.013. Epub 2016 Jan 23.
341	PABPN1 suppresses TDP-43 toxicity in ALS disease models.Hum Mol Genet. 2015 Sep 15;24(18):5154-73. doi: 10.1093/hmg/ddv238. Epub 2015 Jun 30.
342	Downregulated Glia Interplay and Increased miRNA-155 as Promising Markers to Track ALS at anEarly Stage.Mol Neurobiol. 2018 May;55(5):4207-4224. doi: 10.1007/s12035-017-0631-2. Epub 2017 Jun 13.
343	Species-dependent neuropathology in transgenic SOD1 pigs.Cell Res. 2014 Apr;24(4):464-81. doi: 10.1038/cr.2014.25. Epub 2014 Feb 28.
344	Theme 7 Pre-clinical therapeutic strategies.Amyotroph Lateral Scler Frontotemporal Degener. 2019 Nov;20(sup1):217-245. doi: 10.1080/21678421.2019.1646995.
345	Profilin 1 associates with stress granules and ALS-linked mutations alter stress granule dynamics.J Neurosci. 2014 Jun 11;34(24):8083-97. doi: 10.1523/JNEUROSCI.0543-14.2014.
346	Protein interacting with C kinase and neurological disorders.Synapse. 2013 Aug;67(8):532-40. doi: 10.1002/syn.21657. Epub 2013 Mar 20.
347	Distinct multilevel misregulations of Parkin and PINK1 revealed in cell and animal models of TDP-43 proteinopathy.Cell Death Dis. 2018 Sep 20;9(10):953. doi: 10.1038/s41419-018-1022-y.
348	Genetic ablation of phospholipase C delta 1 increases survival in SOD1(G93A) mice.Neurobiol Dis. 2013 Dec;60:11-7. doi: 10.1016/j.nbd.2013.08.006. Epub 2013 Aug 19.
349	Alteration of POLDIP3 splicing associated with loss of function of TDP-43 in tissues affected with ALS.PLoS One. 2012;7(8):e43120. doi: 10.1371/journal.pone.0043120. Epub 2012 Aug 10.
350	PGC-1 sparks the fire of neuroprotection against neurodegenerative disorders.Ageing Res Rev. 2018 Jul;44:8-21. doi: 10.1016/j.arr.2018.03.004. Epub 2018 Mar 23.
351	Increased GADD34 in oligodendrocytes in Alzheimer's disease.Neurosci Lett. 2015 Aug 18;602:50-5. doi: 10.1016/j.neulet.2015.06.052. Epub 2015 Jul 2.
352	Protein arginine methyltransferase 1 and 8 interact with FUS to modify its sub-cellular distribution and toxicity in vitro and in vivo.PLoS One. 2013 Apr 19;8(4):e61576. doi: 10.1371/journal.pone.0061576. Print 2013.
353	Co-localization of cystatin C and prosaposin in cultured neurons and in anterior horn neurons with amyotrophic lateral sclerosis.J Neurol Sci. 2018 Jan 15;384:67-74. doi: 10.1016/j.jns.2017.11.023. Epub 2017 Nov 20.
354	Novel autoantibodies against the proteasome subunit PSMA7 in amyotrophic lateral sclerosis.J Neuroimmunol. 2018 Dec 15;325:54-60. doi: 10.1016/j.jneuroim.2018.09.013. Epub 2018 Oct 1.
355	Degeneration of proprioceptive sensory nerve endings in mice harboring amyotrophic lateral sclerosis-causing mutations.J Comp Neurol. 2015 Dec 1;523(17):2477-94. doi: 10.1002/cne.23848. Epub 2015 Jul 21.
356	Rab1-dependent ER-Golgi transport dysfunction is a common pathogenic mechanism in SOD1, TDP-43 and FUS-associated ALS.Acta Neuropathol. 2015 Nov;130(5):679-97. doi: 10.1007/s00401-015-1468-2. Epub 2015 Aug 23.
357	C9orf72 and RAB7L1 regulate vesicle trafficking in amyotrophic lateral sclerosis and frontotemporal dementia.Brain. 2017 Apr 1;140(4):887-897. doi: 10.1093/brain/awx024.
358	Monozygotic twins and triplets discordant for amyotrophic lateral sclerosis display differential methylation and gene expression.Sci Rep. 2019 Jun 4;9(1):8254. doi: 10.1038/s41598-019-44765-4.
359	The C9orf72 repeat expansion disrupts nucleocytoplasmic transport.Nature. 2015 Sep 3;525(7567):56-61. doi: 10.1038/nature14973. Epub 2015 Aug 26.
360	Znf179 E3 ligase-mediated TDP-43 polyubiquitination is involved in TDP-43- ubiquitinated inclusions (UBI) (+)-related neurodegenerative pathology.J Biomed Sci. 2018 Nov 8;25(1):76. doi: 10.1186/s12929-018-0479-4.
361	RPS25 is required for efficient RAN translation of C9orf72 and other neurodegenerative disease-associated nucleotide repeats.Nat Neurosci. 2019 Sep;22(9):1383-1388. doi: 10.1038/s41593-019-0455-7. Epub 2019 Jul 29.
362	SAGE analysis of genes differentially expressed in presymptomatic TgSOD1G93A transgenic mice identified cellular processes involved in early stage of ALS pathology.J Mol Neurosci. 2010 May;41(1):172-82. doi: 10.1007/s12031-009-9317-1. Epub 2009 Dec 2.
363	Chromogranin peptides in amyotrophic lateral sclerosis.Regul Pept. 2009 Jan 8;152(1-3):13-21. doi: 10.1016/j.regpep.2008.07.009. Epub 2008 Aug 5.
364	Association analysis of four candidate genetic variants with sporadic amyotrophic lateral sclerosis in a Chinese population.Neurol Sci. 2014 Jul;35(7):1089-95. doi: 10.1007/s10072-014-1656-1. Epub 2014 Feb 4.
365	The C9orf72-interacting protein Smcr8 is a negative regulator of autoimmunity and lysosomal exocytosis.Genes Dev. 2018 Jul 1;32(13-14):929-943. doi: 10.1101/gad.313932.118. Epub 2018 Jun 27.
366	Whole-genome sequencing reveals a coding non-pathogenic variant tagging a non-coding pathogenic hexanucleotide repeat expansion in C9orf72 as cause of amyotrophic lateral sclerosis.Hum Mol Genet. 2012 Jun 1;21(11):2412-9. doi: 10.1093/hmg/dds055. Epub 2012 Feb 17.
367	Diagnostic and prognostic power of CSF Tau in amyotrophic lateral sclerosis.J Neurol. 2018 Oct;265(10):2353-2362. doi: 10.1007/s00415-018-9008-3. Epub 2018 Aug 16.
368	SUMO3 modification accelerates the aggregation of ALS-linked SOD1 mutants.PLoS One. 2014 Jun 27;9(6):e101080. doi: 10.1371/journal.pone.0101080. eCollection 2014.
369	Whole genome analyses reveal no pathogenetic single nucleotide or structural differences between monozygotic twins discordant for amyotrophic lateral sclerosis.Amyotroph Lateral Scler Frontotemporal Degener. 2015;16(5-6):385-92. doi: 10.3109/21678421.2015.1040029. Epub 2015 May 11.
370	Dysregulation of a novel miR-1825/TBCB/TUBA4A pathway in sporadic and familial ALS.Cell Mol Life Sci. 2018 Dec;75(23):4301-4319. doi: 10.1007/s00018-018-2873-1. Epub 2018 Jul 20.
371	Genetic analysis of TIA1 gene in Chinese patients with amyotrophic lateral sclerosis.Neurobiol Aging. 2018 Jul;67:201.e9-201.e10. doi: 10.1016/j.neurobiolaging.2018.03.020. Epub 2018 Mar 23.
372	A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers.Brain. 2018 Oct 1;141(10):2895-2907. doi: 10.1093/brain/awy238.
373	VCP maintains lysosomal homeostasis and TFEB activity in differentiated skeletal muscle.Autophagy. 2019 Jun;15(6):1082-1099. doi: 10.1080/15548627.2019.1569933. Epub 2019 Jan 29.
374	Transcription elongation factor AFF2/FMR2 regulates expression of expanded GGGGCC repeat-containing C9ORF72 allele in ALS/FTD.Nat Commun. 2019 Nov 29;10(1):5466. doi: 10.1038/s41467-019-13477-8.
375	Identification of biomarkers for amyotrophic lateral sclerosis by comprehensive analysis of exosomal mRNAs in human cerebrospinal fluid.BMC Med Genomics. 2019 Jan 10;12(1):7. doi: 10.1186/s12920-019-0473-z.
376	Muscle specific kinase (MuSK) activation preserves neuromuscular junctions in the diaphragm but is not sufficient to provide a functional benefit in the SOD1(G93A) mouse model of ALS.Neurobiol Dis. 2019 Apr;124:340-352. doi: 10.1016/j.nbd.2018.12.002. Epub 2018 Dec 4.
377	Genome wide analysis reveals heparan sulfate epimerase modulates TDP-43 proteinopathy.PLoS Genet. 2019 Dec 13;15(12):e1008526. doi: 10.1371/journal.pgen.1008526. eCollection 2019 Dec.
378	NPGPx-Mediated Adaptation to Oxidative Stress Protects Motor Neurons from Degeneration in Aging by Directly Modulating O-GlcNAcase.Cell Rep. 2019 Nov 19;29(8):2134-2143.e7. doi: 10.1016/j.celrep.2019.10.053.
379	Investigation of mitochondrial calcium uniporter role in embryonic and adult motor neurons from G93A(hSOD1) mice.Neurobiol Aging. 2019 Mar;75:209-222. doi: 10.1016/j.neurobiolaging.2018.11.019. Epub 2018 Nov 23.
380	Spy1, a unique cell cycle regulator, alters viability in ALS motor neurons and cell lines in response to mutant SOD1-induced DNA damage.DNA Repair (Amst). 2019 Feb;74:51-62. doi: 10.1016/j.dnarep.2018.12.005. Epub 2018 Dec 21.
381	SUPT4H1 Depletion Leads to a Global Reduction in RNA.Cell Rep. 2019 Jan 2;26(1):45-53.e4. doi: 10.1016/j.celrep.2018.12.004.
382	CCNF mutations in amyotrophic lateral sclerosis and frontotemporal dementia. Nat Commun. 2016 Apr 15;7:11253. doi: 10.1038/ncomms11253.
383	Two novel mutations in conserved codons indicate that CHCHD10 is a gene associated with motor neuron disease. Brain. 2014 Dec;137(Pt 12):e309. doi: 10.1093/brain/awu227. Epub 2014 Aug 11.
384	Mutations in CHMP2B in lower motor neuron predominant amyotrophic lateral sclerosis (ALS). PLoS One. 2010 Mar 24;5(3):e9872. doi: 10.1371/journal.pone.0009872.
385	Deleterious mutations in the essential mRNA metabolism factor, hGle1, in amyotrophic lateral sclerosis. Hum Mol Genet. 2015 Mar 1;24(5):1363-73. doi: 10.1093/hmg/ddu545. Epub 2014 Oct 24.
386	Mutations in the Matrin 3 gene cause familial amyotrophic lateral sclerosis. Nat Neurosci. 2014 May;17(5):664-666. doi: 10.1038/nn.3688. Epub 2014 Mar 30.
387	Mutations in the profilin 1 gene cause familial amyotrophic lateral sclerosis. Nature. 2012 Aug 23;488(7412):499-503. doi: 10.1038/nature11280.
388	ALS2CL, the novel protein highly homologous to the carboxy-terminal half of ALS2, binds to Rab5 and modulates endosome dynamics.FEBS Lett. 2004 Sep 24;575(1-3):64-70. doi: 10.1016/j.febslet.2004.07.092.
389	Altered expression of cardiac ankyrin repeat protein and its homologue, ankyrin repeat protein with PEST and proline-rich region, in atrophic muscles in amyotrophic lateral sclerosis.Pathobiology. 2002-2003;70(4):197-203. doi: 10.1159/000069329.
390	NF-B and IRF1 Induce Endogenous Retrovirus K Expression via Interferon-Stimulated Response Elements in Its 5' Long Terminal Repeat.J Virol. 2016 Sep 29;90(20):9338-49. doi: 10.1128/JVI.01503-16. Print 2016 Oct 15.
391	Amyotrophic lateral sclerosis, lead, and genetic susceptibility: polymorphisms in the delta-aminolevulinic acid dehydratase and vitamin D receptor genes.Environ Health Perspect. 2003 Aug;111(10):1335-9. doi: 10.1289/ehp.6109.
392	Mutations in ATP13A2 (PARK9) are associated with an amyotrophic lateral sclerosis-like phenotype, implicating this locus in further phenotypic expansion.Hum Genomics. 2019 Apr 16;13(1):19. doi: 10.1186/s40246-019-0203-9.
393	ATXN1 intermediate-length polyglutamine expansions are associated with amyotrophic lateral sclerosis.Neurobiol Aging. 2018 Apr;64:157.e1-157.e5. doi: 10.1016/j.neurobiolaging.2017.11.011. Epub 2017 Nov 28.
394	Expression of calbindin-D28K in motoneuron hybrid cells after retroviral infection with calbindin-D28K cDNA prevents amyotrophic lateral sclerosis IgG-mediated cytotoxicity.Proc Natl Acad Sci U S A. 1996 Jun 25;93(13):6796-801. doi: 10.1073/pnas.93.13.6796.
395	Limited effects of glatiramer acetate in the high-copy number hSOD1-G93A mouse model of ALS.Exp Neurol. 2007 Aug;206(2):288-95. doi: 10.1016/j.expneurol.2007.05.007. Epub 2007 May 18.
396	DNA base-excision repair enzyme apurinic/apyrimidinic endonuclease/redox factor-1 is increased and competent in the brain and spinal cord of individuals with amyotrophic lateral sclerosis.Neuromolecular Med. 2002;2(1):47-60. doi: 10.1007/s12017-002-0038-7.
397	Dystrophin-related protein in skeletal muscles in neuromuscular disorders: immunohistochemical study.Acta Neuropathol. 1993;85(3):256-9. doi: 10.1007/BF00227719.
398	VAPB/ALS8 interacts with FFAT-like proteins including the p97 cofactor FAF1 and the ASNA1 ATPase.BMC Biol. 2014 May 29;12:39. doi: 10.1186/1741-7007-12-39.
399	CSF chitinase proteins in amyotrophic lateral sclerosis.J Neurol Neurosurg Psychiatry. 2019 Nov;90(11):1215-1220. doi: 10.1136/jnnp-2019-320442. Epub 2019 May 23.
400	Upregulation of Bax protein and increased DNA degradation in ALS spinal cord motor neurons.Acta Neurol Scand. 1999 Nov;100(5):317-21. doi: 10.1111/j.1600-0404.1999.tb00403.x.
401	The split hand in amyotrophic lateral sclerosis: a possible role for the neuromuscular junction.Amyotroph Lateral Scler Frontotemporal Degener. 2019 Aug;20(5-6):368-375. doi: 10.1080/21678421.2019.1606245. Epub 2019 May 6.
402	Recent advances in the genetics of amyotrophic lateral sclerosis and frontotemporal dementia: common pathways in neurodegenerative disease.Hum Mol Genet. 2006 Oct 15;15 Spec No 2:R182-7. doi: 10.1093/hmg/ddl202.
403	SMN complex member Gemin3 self-interacts and has a functional relationship with ALS-linked proteins TDP-43, FUS and Sod1.Sci Rep. 2019 Dec 10;9(1):18666. doi: 10.1038/s41598-019-53508-4.
404	A small-molecule inhibitor of SOD1-Derlin-1 interaction ameliorates pathology in an ALS mouse model.Nat Commun. 2018 Jul 10;9(1):2668. doi: 10.1038/s41467-018-05127-2.
405	Neuronal NOS is dislocated during muscle atrophy in amyotrophic lateral sclerosis.J Neurol Sci. 2010 Jul 15;294(1-2):95-101. doi: 10.1016/j.jns.2010.03.022.
406	Analysis of DPP6 and FGGY as candidate genes for amyotrophic lateral sclerosis.Amyotroph Lateral Scler. 2010 Aug;11(4):389-91. doi: 10.3109/17482960903358857.
407	Inhibitory synaptic regulation of motoneurons: a new target of disease mechanisms in amyotrophic lateral sclerosis.Mol Neurobiol. 2012 Feb;45(1):30-42. doi: 10.1007/s12035-011-8217-x. Epub 2011 Nov 10.
408	Increased expression level of the splicing variant of SIP1 in motor neuron diseases.Int J Biochem Cell Biol. 2002 Jun;34(6):699-707. doi: 10.1016/s1357-2725(01)00150-9.
409	Expression of GDNF receptor (RET and GDNFR-alpha) mRNAs in the spinal cord of patients with amyotrophic lateral sclerosis.Brain Res. 1999 Feb 27;820(1-2):77-85. doi: 10.1016/s0006-8993(98)01344-4.
410	Stratification of amyotrophic lateral sclerosis patients: a crowdsourcing approach.Sci Rep. 2019 Jan 24;9(1):690. doi: 10.1038/s41598-018-36873-4.
411	Early decrease of survival factors and DNA repair enzyme in spinal motor neurons of presymptomatic transgenic mice that express a mutant SOD1 gene.Life Sci. 2002 Dec 20;72(4-5):541-8. doi: 10.1016/s0024-3205(02)02249-x.
412	Agrin and LRP4 antibodies as new biomarkers of myasthenia gravis.Ann N Y Acad Sci. 2018 Feb;1413(1):126-135. doi: 10.1111/nyas.13573. Epub 2018 Jan 28.
413	U1 snRNP is mislocalized in ALS patient fibroblasts bearing NLS mutations in FUS and is required for motor neuron outgrowth in zebrafish.Nucleic Acids Res. 2015 Mar 31;43(6):3208-18. doi: 10.1093/nar/gkv157. Epub 2015 Mar 3.
414	Expression of myoglobin gene in skeletal muscle of patients with neuromuscular diseases.Muscle Nerve. 1994 Jul;17(7):720-4. doi: 10.1002/mus.880170703.
415	Nitration and Glycation Turn Mature NGF into a Toxic Factor for Motor Neurons: A Role for p75(NTR) and RAGE Signaling in ALS.Antioxid Redox Signal. 2018 Jun 20;28(18):1587-1602. doi: 10.1089/ars.2016.6966. Epub 2017 Jun 26.
416	Expression of different metallothionein messenger ribonucleic acids in motor cortex, spinal cord and liver from patients with amyotrophic lateral sclerosis.J Neurol Sci. 1996 Oct;142(1-2):39-44. doi: 10.1016/0022-510x(96)00013-5.
417	Genetic and clinical analysis of spinocerebellar ataxia type 36 in Mainland China.Clin Genet. 2016 Aug;90(2):141-8. doi: 10.1111/cge.12706. Epub 2016 Jan 20.
418	ERp57 is protective against mutant SOD1-induced cellular pathology in amyotrophic lateral sclerosis.Hum Mol Genet. 2018 Apr 15;27(8):1311-1331. doi: 10.1093/hmg/ddy041.
419	Two sites in the MAPT region confer genetic risk for Guam ALS/PDC and dementia.Hum Mol Genet. 2007 Feb 1;16(3):295-306. doi: 10.1093/hmg/ddl463. Epub 2006 Dec 21.
420	Deletion of the endogenous TrkB.T1 receptor isoform restores the number of hippocampal CA1 parvalbumin-positive neurons and rescues long-term potentiation in pre-symptomatic mSOD1(G93A) ALS mice.Mol Cell Neurosci. 2018 Jun;89:33-41. doi: 10.1016/j.mcn.2018.03.010. Epub 2018 Mar 24.
421	Loss of endosomal recycling factor RAB11 coupled with complex regulation of MAPK/ERK/AKT signaling in postmortem spinal cord specimens of sporadic amyotrophic lateral sclerosis patients.Mol Brain. 2019 Jun 13;12(1):55. doi: 10.1186/s13041-019-0475-y.
422	Rab5 and Alsin regulate stress-activated cytoprotective signaling on mitochondria.Elife. 2018 Feb 22;7:e32282. doi: 10.7554/eLife.32282.
423	Microglial activation in an amyotrophic lateral sclerosis-like model caused by Ranbp2 loss and nucleocytoplasmic transport impairment in retinal ganglion neurons.Cell Mol Life Sci. 2019 Sep;76(17):3407-3432. doi: 10.1007/s00018-019-03078-5. Epub 2019 Apr 3.
424	C9orf72, a protein associated with amyotrophic lateral sclerosis (ALS) is a guanine nucleotide exchange factor.PeerJ. 2018 Oct 17;6:e5815. doi: 10.7717/peerj.5815. eCollection 2018.
425	Amyotrophic lateral sclerosis-associated mutant SOD1 inhibits anterograde axonal transport of mitochondria by reducing Miro1 levels.Hum Mol Genet. 2017 Dec 1;26(23):4668-4679. doi: 10.1093/hmg/ddx348.
426	Necroptosis is dispensable for motor neuron degeneration in a mouse model of ALS.Cell Death Differ. 2020 May;27(5):1728-1739. doi: 10.1038/s41418-019-0457-8. Epub 2019 Nov 19.
427	Loss of RAD-23 Protects Against Models of Motor Neuron Disease by Enhancing Mutant Protein Clearance.J Neurosci. 2015 Oct 21;35(42):14286-306. doi: 10.1523/JNEUROSCI.0642-15.2015.
428	Does SCFD1 rs10139154 Polymorphism Decrease Alzheimer's Disease Risk?.J Mol Neurosci. 2019 Oct;69(2):343-350. doi: 10.1007/s12031-019-01363-3. Epub 2019 Jul 2.
429	Tracking Effects of SIL1 Increase: Taking a Closer Look Beyond the Consequences of Elevated Expression Level.Mol Neurobiol. 2018 Mar;55(3):2524-2546. doi: 10.1007/s12035-017-0494-6. Epub 2017 Apr 11.
430	Removing dysfunctional mitochondria from axons independent of mitophagy under pathophysiological conditions.Autophagy. 2017 Oct 3;13(10):1792-1794. doi: 10.1080/15548627.2017.1356552. Epub 2017 Aug 16.
431	Heterozygous S44L missense change of the spastin gene in amyotrophic lateral sclerosis.Amyotroph Lateral Scler. 2008 Aug;9(4):251-3. doi: 10.1080/17482960801900172.
432	Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration.Nat Neurosci. 2019 Feb;22(2):180-190. doi: 10.1038/s41593-018-0293-z. Epub 2019 Jan 14.
433	TFEB dysregulation as a driver of autophagy dysfunction in neurodegenerative disease: Molecular mechanisms, cellular processes, and emerging therapeutic opportunities.Neurobiol Dis. 2019 Feb;122:83-93. doi: 10.1016/j.nbd.2018.05.012. Epub 2018 May 28.
434	Biological Assessment of a (18)F-Labeled Sulforhodamine 101 in a Mouse Model of Alzheimer's Disease as a Potential Astrocytosis Marker.Front Neurosci. 2019 Jul 16;13:734. doi: 10.3389/fnins.2019.00734. eCollection 2019.
435	Neuropathy-causing mutations in HSPB1 impair autophagy by disturbing the formation of SQSTM1/p62 bodies.Autophagy. 2019 Jun;15(6):1051-1068. doi: 10.1080/15548627.2019.1569930. Epub 2019 Jan 31.
436	ADAR2 mislocalization and widespread RNA editing aberrations in C9orf72-mediated ALS/FTD.Acta Neuropathol. 2019 Jul;138(1):49-65. doi: 10.1007/s00401-019-01999-w. Epub 2019 Apr 3.
437	Theme 1 Epidemiology and informatics.Amyotroph Lateral Scler Frontotemporal Degener. 2019 Nov;20(sup1):101-113. doi: 10.1080/21678421.2019.1646989.
438	A genome-wide association study on amyotrophic lateral sclerosis in the Taiwanese Han population.Biomark Med. 2016 Jun;10(6):597-611. doi: 10.2217/bmm.15.115. Epub 2015 Nov 18.
439	Reaction to Endoplasmic Reticulum Stress via ATF6 in Amyotrophic Lateral Sclerosis Deteriorates With Aging.Front Aging Neurosci. 2019 Jan 25;11:5. doi: 10.3389/fnagi.2019.00005. eCollection 2019.
440	ALS and MMN mimics in patients with BSCL2 mutations: the expanding clinical spectrum of SPG17 hereditary spastic paraplegia.J Neurol. 2017 Jan;264(1):11-20. doi: 10.1007/s00415-016-8301-2. Epub 2016 Oct 13.
441	Association of a Locus in the CAMTA1 Gene With Survival in Patients With Sporadic Amyotrophic Lateral Sclerosis.JAMA Neurol. 2016 Jul 1;73(7):812-20. doi: 10.1001/jamaneurol.2016.1114.
442	The p150 subunit of dynactin (DCTN1) gene in multiple sclerosis.Acta Neurol Scand. 2007 Oct;116(4):231-4. doi: 10.1111/j.1600-0404.2007.00884.x.
443	Chromogranin A levels in the cerebrospinal fluid of patients with amyotrophic lateral sclerosis.Neurobiol Aging. 2018 Jul;67:21-22. doi: 10.1016/j.neurobiolaging.2018.02.017. Epub 2018 Feb 27.
444	Quantitative analysis of human endogenous retrovirus-K transcripts in postmortem premotor cortex fails to confirm elevated expression of HERV-K RNA in amyotrophic lateral sclerosis.Acta Neuropathol Commun. 2019 Mar 18;7(1):45. doi: 10.1186/s40478-019-0698-2.
445	Primary Neurons and Differentiated NSC-34 Cells Are More Susceptible to Arginine-Rich ALS Dipeptide Repeat Protein-Associated Toxicity than Non-Differentiated NSC-34 and CHO Cells.Int J Mol Sci. 2019 Dec 11;20(24):6238. doi: 10.3390/ijms20246238.
446	ALS-associated peripherin spliced transcripts form distinct protein inclusions that are neuroprotective against oxidative stress.Exp Neurol. 2014 Nov;261:217-29. doi: 10.1016/j.expneurol.2014.05.024. Epub 2014 Jun 4.
447	Protein kinase CK2 modulates HSJ1 function through phosphorylation of the UIM2 domain.Hum Mol Genet. 2017 Feb 1;26(3):611-623. doi: 10.1093/hmg/ddw420.
448	The Fine Tuning of Drp1-Dependent Mitochondrial Remodeling and Autophagy Controls Neuronal Differentiation.Front Cell Neurosci. 2019 Apr 4;13:120. doi: 10.3389/fncel.2019.00120. eCollection 2019.
449	Animal and cellular models of familial dysautonomia.Clin Auton Res. 2017 Aug;27(4):235-243. doi: 10.1007/s10286-017-0438-2. Epub 2017 Jun 30.
450	Elongator subunit 3 (ELP3) modifies ALS through tRNA modification.Hum Mol Genet. 2018 Apr 1;27(7):1276-1289. doi: 10.1093/hmg/ddy043.
451	Mice deficient in Epg5 exhibit selective neuronal vulnerability to degeneration.J Cell Biol. 2013 Mar 18;200(6):731-41. doi: 10.1083/jcb.201211014. Epub 2013 Mar 11.
452	Genome-wide synthetic lethal CRISPR screen identifies FIS1 as a genetic interactor of ALS-linked C9ORF72.Brain Res. 2020 Feb 1;1728:146601. doi: 10.1016/j.brainres.2019.146601. Epub 2019 Dec 13.
453	MAPT (Tau) expression is a biomarker for an increased rate of survival in pediatric neuroblastoma.Cell Cycle. 2018;17(21-22):2474-2483. doi: 10.1080/15384101.2018.1542898. Epub 2018 Nov 18.
454	Cross-ethnic meta-analysis identifies association of the GPX3-TNIP1 locus with amyotrophic lateral sclerosis.Nat Commun. 2017 Sep 20;8(1):611. doi: 10.1038/s41467-017-00471-1.
455	Residual association at C9orf72 suggests an alternative amyotrophic lateral sclerosis-causing hexanucleotide repeat.Neurobiol Aging. 2013 Sep;34(9):2234.e1-7. doi: 10.1016/j.neurobiolaging.2013.03.003. Epub 2013 Apr 12.
456	Linking hnRNP Function to ALS and FTD Pathology.Front Neurosci. 2018 May 15;12:326. doi: 10.3389/fnins.2018.00326. eCollection 2018.
457	The C9ORF72 GGGGCC expansion forms RNA G-quadruplex inclusions and sequesters hnRNP H to disrupt splicing in ALS brains.Elife. 2016 Sep 13;5:e17820. doi: 10.7554/eLife.17820.
458	Co-occurrence of amyotrophic lateral sclerosis and Charcot-Marie-Tooth disease type 2A in a patient with a novel mutation in the mitofusin-2 gene.Neuromuscul Disord. 2011 Feb;21(2):129-31. doi: 10.1016/j.nmd.2010.09.009. Epub 2010 Oct 14.
459	Quantitative neuromuscular ultrasound analysis as biomarkers in amyotrophic lateral sclerosis.Eur Radiol. 2019 Aug;29(8):4266-4275. doi: 10.1007/s00330-018-5943-8. Epub 2019 Jan 21.
460	Second-generation Irish genome-wide association study for amyotrophic lateral sclerosis.Neurobiol Aging. 2015 Feb;36(2):1221.e7-13. doi: 10.1016/j.neurobiolaging.2014.08.030. Epub 2014 Sep 6.
461	Dysregulation of human NEFM and NEFH mRNA stability by ALS-linked miRNAs.Mol Brain. 2018 Jul 20;11(1):43. doi: 10.1186/s13041-018-0386-3.
462	Neuronal over-expression of Oxr1 is protective against ALS-associated mutant TDP-43 mislocalisation in motor neurons and neuromuscular defects in vivo.Hum Mol Genet. 2019 Nov 1;28(21):3584-3599. doi: 10.1093/hmg/ddz190.
463	Alzheimer disease and amyotrophic lateral sclerosis: an etiopathogenic connection.Acta Neuropathol. 2014 Feb;127(2):243-56. doi: 10.1007/s00401-013-1175-9. Epub 2013 Oct 18.
464	SOD1/Rag2 Mice with Low Copy Number of SOD1 Gene as a New Long-Living Immunodeficient Model of ALS.Sci Rep. 2019 Jan 28;9(1):799. doi: 10.1038/s41598-018-37235-w.
465	Motor-Coordinative and Cognitive Dysfunction Caused by Mutant TDP-43 Could Be Reversed by Inhibiting Its Mitochondrial Localization.Mol Ther. 2017 Jan 4;25(1):127-139. doi: 10.1016/j.ymthe.2016.10.013. Epub 2017 Jan 4.
466	Systemic administration of scAAV9-IGF1 extends survival in SOD1(G93A) ALS mice via inhibiting p38 MAPK and the JNK-mediated apoptosis pathway.Brain Res Bull. 2018 May;139:203-210. doi: 10.1016/j.brainresbull.2018.02.015. Epub 2018 Feb 27.
467	Exploring the aggregation-prone regions from structural domains of human TDP-43.Biochim Biophys Acta Proteins Proteom. 2019 Mar;1867(3):286-296. doi: 10.1016/j.bbapap.2018.10.008. Epub 2018 Oct 11.
468	The role of the protein-RNA recognition code in neurodegeneration.Cell Mol Life Sci. 2019 Jun;76(11):2043-2058. doi: 10.1007/s00018-019-03096-3. Epub 2019 Apr 12.
469	Distinct and shared functions of ALS-associated proteins TDP-43, FUS and TAF15 revealed by multisystem analyses.Nat Commun. 2016 Jul 5;7:12143. doi: 10.1038/ncomms12143.
470	Mutation of the caspase-3 cleavage site in the astroglial glutamate transporter EAAT2 delays disease progression and extends lifespan in the SOD1-G93A mouse model of ALS.Exp Neurol. 2017 Jun;292:145-153. doi: 10.1016/j.expneurol.2017.03.014. Epub 2017 Mar 22.
471	A two-stage genome-wide association study of sporadic amyotrophic lateral sclerosis.Hum Mol Genet. 2009 Apr 15;18(8):1524-32. doi: 10.1093/hmg/ddp059. Epub 2009 Feb 4.
472	Neuropathological characterization of a novel TANK binding kinase (TBK1) gene loss of function mutation associated with amyotrophic lateral sclerosis.Neuropathol Appl Neurobiol. 2020 Apr;46(3):279-291. doi: 10.1111/nan.12578. Epub 2019 Oct 28.
473	RNA-seq analyses reveal that cervical spinal cords and anterior motor neurons from amyotrophic lateral sclerosis subjects show reduced expression of mitochondrial DNA-encoded respiratory genes, and rhTFAM may correct this respiratory deficiency.Brain Res. 2017 Jul 15;1667:74-83. doi: 10.1016/j.brainres.2017.05.010. Epub 2017 May 13.
474	Defining the association of TMEM106B variants among frontotemporal lobar degeneration patients with GRN mutations andC9orf72 repeat expansions.Neurobiol Aging. 2014 Nov;35(11):2658.e1-2658.e5. doi: 10.1016/j.neurobiolaging.2014.06.023. Epub 2014 Jun 28.
475	R521C and R521H mutations in FUS result in weak binding with Karyopherin2 leading to Amyotrophic lateral sclerosis: a molecular docking and dynamics study.J Biomol Struct Dyn. 2017 Aug;35(10):2169-2185. doi: 10.1080/07391102.2016.1209130. Epub 2016 Aug 8.
476	ATXN2 with intermediate-length CAG/CAA repeats does not seem to be a risk factor in hereditary spastic paraplegia.J Neurol Sci. 2012 Oct 15;321(1-2):100-2. doi: 10.1016/j.jns.2012.07.036. Epub 2012 Aug 3.
477	Collagen XIX Alpha 1 Improves Prognosis in Amyotrophic Lateral Sclerosis.Aging Dis. 2019 Apr 1;10(2):278-292. doi: 10.14336/AD.2018.0917. eCollection 2019 Apr.
478	ERCC6L2 rs591486 polymorphism and risk for amyotrophic lateral sclerosis in Greek population.Neurol Sci. 2019 Jun;40(6):1237-1244. doi: 10.1007/s10072-019-03825-3. Epub 2019 Mar 16.
479	Elucidating the Contribution of Skeletal Muscle Ion Channels to Amyotrophic Lateral Sclerosis in search of new therapeutic options.Sci Rep. 2019 Feb 28;9(1):3185. doi: 10.1038/s41598-019-39676-3.
480	Rare variants in MYH15 modify amyotrophic lateral sclerosis risk.Hum Mol Genet. 2019 Jul 15;28(14):2309-2318. doi: 10.1093/hmg/ddz063.
481	HR23B pathology preferentially co-localizes with p62, pTDP-43 and poly-GA in C9ORF72-linked frontotemporal dementia and amyotrophic lateral sclerosis.Acta Neuropathol Commun. 2019 Mar 13;7(1):39. doi: 10.1186/s40478-019-0694-6.
482	Combined Tissue-Fluid Proteomics to Unravel Phenotypic Variability in Amyotrophic Lateral Sclerosis.Sci Rep. 2019 Mar 14;9(1):4478. doi: 10.1038/s41598-019-40632-4.
483	White matter changes in the perforant path area in patients with amyotrophic lateral sclerosis.Neuropathol Appl Neurobiol. 2019 Oct;45(6):570-585. doi: 10.1111/nan.12555. Epub 2019 May 14.
484	The VAPB-PTPIP51 endoplasmic reticulum-mitochondria tethering proteins are present in neuronal synapses and regulate synaptic activity.Acta Neuropathol Commun. 2019 Mar 6;7(1):35. doi: 10.1186/s40478-019-0688-4.
485	Network approach identifies Pacer as an autophagy protein involved in ALS pathogenesis.Mol Neurodegener. 2019 Mar 27;14(1):14. doi: 10.1186/s13024-019-0313-9.
486	Sarm1 deletion suppresses TDP-43-linked motor neuron degeneration and cortical spine loss.Acta Neuropathol Commun. 2019 Oct 28;7(1):166. doi: 10.1186/s40478-019-0800-9.
487	Motor neuron degeneration in spastic paraplegia 11 mimics amyotrophic lateral sclerosis lesions.Brain. 2016 Jun;139(Pt 6):1723-34. doi: 10.1093/brain/aww061. Epub 2016 Mar 25.
488	Carboxyl-terminal modulator protein regulates Akt signaling during skeletal muscle atrophy in vitro and a mouse model of amyotrophic lateral sclerosis.Sci Rep. 2019 Mar 8;9(1):3920. doi: 10.1038/s41598-019-40553-2.